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CHAPTER I
STATEMENT OF THE PROBLEM
The advances in healthcare and scientific knowledge have resulted in longer life
expectancies in both men and women; the average life expectancy of a woman in United
States is now 81.2 years old [1]. These advanced ages in women now means that they are
experiencing the effects of age-related changes in the body for much longer periods of
time, mainly reproductive senescence, resulting in the loss of circulating ovarian
hormones. The age at which menopause occurs has not changed, resulting in women now
living over a third of their lives in a postmenopausal state.
The major circulating estrogen produced by the ovaries, 17β-estradiol (E2), has
many homeostatic effects in the body like neuroprotection, cognition, stress responses,
cardioprotection, and bone density. During aging and reproductive senescence, all these
physiological processes are affected and generally result in negative outcomes for
women: osteoporosis, cardiovascular disease, stroke, and cognitive impairment. Hormone
replacement therapy (HT) was to become the standard in treating women undergoing
reproductive senescence in order to abrogate the negative effects associated with the
decline in circulating E2. These effects, as well as HT efficacy, were investigated in the
Women’s Health Initiative (WHI) and Women's Health Initiative Memory Studies
(WHIMS). Both studies were aimed at investigating how HT would impact health issues
in aging women through a large-scale study based on previous experiments conducted in
1	
  

	
  

animals that had demonstrated the positive effects of HT. While the WHI studies were
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ended abruptly due to negative consequences associated with the study, later analysis
from these studies brought forth some interesting, yet important, observations. The
adverse effects of HT occurred mainly women who were at least 10 years removed from
menopause [2-5]. These adverse effects included cardiovascular and coronary disease,
breast cancer, stroke, and cognitive impairments. However, younger women up to 5 years
postmenopause benefited from the treatments [6, 7]. These findings were later supported
by the Kronos Early Estrogen Prevention Study (KEEPS) and KEEPS Cognitive and
Affective ancillary study that observed positive effects of early estrogen therapy (ET) in
peri-menopausal and early postmenopausal women on cognition, mood, and
cardiovascular disease [8, 9].
These studies, along with others [10, 11], led to the idea of a therapeutic window
in which ET is beneficial, known as the “timing hypothesis” [12], pointing to age-related
adjustments that occur during and after this critical period of declining E2 levels [13].
However, the mechanisms underlying the changing molecular environment of the aging
brain in response to E2 deprivation still remains elusive. Therefore, this dissertation aims
at understanding the molecular changes that occur in the brain in response to age and
diminishing E2 levels and how these changes contribute to the physiology and adaptive
mechanisms the brain undergoes in this critical period of adjustment.
E2 is known to regulate transcription through an important class of nuclear steroid
receptors called estrogen receptors (ERs). ERα and ERβ mediate the actions of E2 upon
binding through interactions within the promoter region of ER-regulated genes. Both ER

	
  

subtypes are subject to alternative splicing, and it is through this process that ERβ splice
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variants arise altering the receptor function and responsiveness to E2 in the brain. Our
laboratory has previously demonstrated that the effects of ERβ splice variants on
mediating gene transcription. We have also demonstrated the effects of E2 deprivation on
microRNA (miRNA) expression and ERβ protein:protein interactions that may impact
ER gene regulation. Therefore, I hypothesized that aging and diminished E2 levels affect
the alternative splicing of ERβ in the aged female brain through altered expression of ERregulated splicing factors.
In order to test this hypothesis, three specific aims were developed (summarized
in Figure 1):
1. Quantify the mRNA expression of ERβ splice variants in various brain regions in
young and aged animals following E2 deprivation and acute E2 treatment. There are
several splice variants of ERβ expressed in the rat, mouse, and human brain. Previous
studies describing the mRNA distribution of ERβ splice variants have been conducted in
the rat, yet the effects of aging and reproductive senescence on splice variant expression
have not been thoroughly investigated. I hypothesize that aging and E2 deprivation
increase alternative splicing events, resulting in an increase of ERβ splice variants, while
treatment with E2 will decrease splice variant expression. Chapter III will explore this
aim.
2. Quantify the mRNA expression of the Nova1 splicing factor within various
regions of aging brain and determine the effects of E2 treatment on the expression of
this splicing factor during E2 withdrawal. Increases in Nova1-regulated alternative

	
  

splicing events were observed in aged male cortex due to an age-related decrease in
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Nova1 expression. I hypothesize that age-related decline in Nova1 expression along with
decreased levels of E2 result in the downregulation of Nova1 and treatment with E2
results in upregulation of Nova1 needed for effective splicing regulation, resulting in
decreased ERβ splice variant expression. Chapter IV will explore this aim.
3. Elucidate a) whether Nova1 regulates ERβ splicing, and how b) E2 affects RNAbinding proteins responsible for mediating transcription. ERβ pre-mRNA transcripts
contain several Nova1 recognition motifs, meaning Nova1 may regulate alternative
splicing of ERβ. ERβ alternative splicing may be enhanced as a result of altered splicing
kinetics. I hypothesize that Nova1 binds to ERβ pre-mRNA during spliceosome assembly
to mediate exon exclusion that results in decreased ERβ variant expression. Also, E2 may
directly or indirectly affect global alternative splicing events by affecting mRNA
expression and activity of RNA polymerase II (RNAPII), as well as other splicing factors
and spliceosome components. Chapters III and IV will explore this aim.
The molecular mechanisms by which HT efficacy changes with age and
increasingly longer periods of E2 deprivation are unknown. I predicted that E2 efficacy in
the brain is decreased with advanced age in females, due to increased levels of ERβ splice
variants. The results from this dissertation show that ERβ alternative splicing is altered in
a brain region-specific manner, along with RNAPII mRNA expression and activity.
These data also demonstrate a role for Nova1 in the regulation of ERβ alternative splicing
and provide putative molecular mechanisms by which the therapeutic window of HT
efficacy is affected.
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Figure 1. Hypothesis of dissertation: a model. Aging and decreased circulating E2
levels affect the alternative splicing of ERβ in the aged female brain through altered
expression of ER-regulated splicing factors (i.e. Nova1), thereby contributing to the
decreased efficacy and negative effects of late HT in women. HT = hormone replacement
therapy; ERβ = estrogen receptor beta; E2 = 17β-estradiol; Nova1 = Neuro-Oncological
Ventral Antigen 1.

	
  

CHAPTER II
REVIEW OF THE LITERATURE
Menopause and Aging
Menopause, also known as reproductive senescence, is the end of a woman's
reproductive years due to termination of the menstrual cycle. The average age of
menopause is approximately 51 years of age, although the National Institutes of Health
(NIH) and National Institute of Child Health and Development (NICHD) report that this
transition can occur between the ages of 45-55 [14]. Prior to the event of menopause, the
production of ovarian hormones begins to deviate from normal reproductive cyclicity due
to loss of hormone-producing ovarian follicles. Levels of the major circulating estrogen
produced by the ovaries, 17β-estradiol (E2), can fluctuate rapidly during this period of
decline, which manifest in a variety of negative physiological symptoms including hot
flashes, memory impairment, and anxiety [15, 16]. Decreased circulating levels of
progesterone also occurs during the menopausal transition due to the lack of corpora lutea
formation. While this transition occurs at a relatively consistent age in women, life
expectancy has steadily increased. The CDC reports that the average life expectancy for a
woman in the United States is about 81.2 years [1]. These statistics indicate that women
are now living over a third of their lives post-menopause, which increases their risk for
developing cognitive disorders, cardiovascular diseases, and breast cancer [17-19]. The
loss of E2 due to menopause is considered a key factor associated with these increased
6	
  

	
  

health risks, further compounding the effects of aging in women. Previous studies using
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animal models have provided evidence that E2 has positive effects on cognition, memory,
anxiety, depression, cardiovascular health, and bone density [8, 20-24].

The Women's Health Initiative Studies and Hormone Replacement Therapy
The Women's Health Initiative (WHI), the Women's Health Initiative Study on
Cognitive Aging (WHISCA), and the Women's Health Initiative Memory Studies
(WHIMS) were conducted to measure the effects of hormone replacement therapy (HT)
in postmenopausal women. At the time, HT was not a novel therapy, as nearly 40% of
women in the U.S. had undergone treatment. The trials enrolled over 27,000 postmenopausal women between the ages of 50-79, including those with prior hysterectomy.
Contrary to earlier work in animal models, the clinical data revealed that HT had little to
no effect on cognitive function in women, and that combined treatments of conjugated
equine estrogen and medroxyprogesterone acetate (CEE/MPA) decreased global
cognitive functioning and increased the risk for mild cognitive impairment [2, 3, 25-27].
The first WHI clinical trials had to be terminated prematurely due to increased incidence
of cardiovascular disease, stroke, and breast cancer, to which the underlying cause was
studied later through multiple meta-analyses and additional clinical trials. Post-hoc
analysis of the WHI trials revealed that the age of the participants was an integral factor
that predicted whether the effects of HT were beneficial or detrimental, however other
factors contributed to the negative outcomes associated with these studies including
choice of reference group, such as women who had previously undergone HT, and

	
  

hormone preparation [6, 28-31]. Additional basic science and observational clinical
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studies since the initial WHI have supported the beneficial effects of HT [9, 32-35].
These studies include the recent Kronos Early Estrogen Prevention Study (KEEPS)
which saw improvement in mood and anxiety [8]. Further meta-analysis by several
groups observed cognitive and additional health benefits in women who received HT for
short term treatments and most notably during perimenopause or early postmenopause [7,
36, 37].
The combined efforts of both scientists and clinicians have yielded the
observation that the age at which a woman undergoes HT is vital to its efficacy. These
observations led us to what we now know as the "timing hypothesis": women who were
more than 10 years removed from the event of menopause were associated with the
negative outcomes of HT, while women who were perimenopausal, or up to 5 years
postmenopause, benefited from HT [12]. Therefore, the window of opportunity for HT is
a very short period of time in relation to a woman's life expectancy, and missing this
critical period may have detrimental health effects [11, 38-41].

Estrogen Receptors
Estrogens actions are mediated primarily through two steroid receptors, Estrogen
Recepter (ER) α and ERβ. These receptors are class I members of the ligand-activated
nuclear receptor superfamily and act as transcription factors for a wide variety of genes
[42]. Early studies on ERs in the 1960s by Jensen and colleagues provided the classical
model of the two-step hypothesis: cytoplasmic-localized ERs bind ligand, undergo

	
  

conformational changes, dimerize, and then translocate to the nucleus to regulate gene
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transcription through DNA-binding and/or association with other transcription factors
[43]. Since 1968, our understanding of ERs and their signaling pathways have been
greatly expanded.
For instance, the discovery that there are two distinct ERs, encoded by separate
genes, provided additional mechanisms through which E2 can mediate its actions [44,
45]. Dimerization of the receptors can occur in a homo- or hetero-typic manner where
ERβ can dimerize with itself or with ERα [46]. Following dimerization, these receptors
then bind to estrogen response elements (EREs) located within the promoter regions of
ER-responsive genes to regulate transcription. High affinity studies of ERα with EREs
described a canonical inverted repeat sequence AGGTCAnnnTGACCT, where ‘n’
represents any nucleotide [47]. This exact sequence rarely occurs naturally, and many
times EREs are variations of this high affinity sequence, including ERE half-sites [4850]. Transcriptional modulation can also occur in an ERE sequence-independent manner,
where increased nucleotide variation results in less activity at these non-canonical EREs
[51]. ERβ is not only able to act in a cis manner at an ERE, but can also act in trans at an
AP-1 site when associated with other transcription factors like c-Jun and c-Fos [52].
The structure of ERβ in the rat (rERβ) contains 6 domains. Each of these
domains, designated A-F, have different functions that work together to transcriptionally
regulate gene expression (Figure 2). The A/B domains comprise the activator function-1
(AF-1) domain that binds to co-regulatory proteins required for transcriptional regulation.
Homology of the A/B domain between ERα and ERβ is only 17%, making this the least

	
  

conserved domain [44, 45] and likely contributes to the distinct functions of each
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receptor subtype. The C domain is the DNA-binding domain (DBD), which recognizes
the ERE sequences within a gene promoter through two zinc fingers motifs. The spacing
of these two zinc fingers allows the helix-loop-helix structure to bind and recognize
canonical ERE sites. The D domain is the nuclear localization domain, which acts as a
hinge region important for conformational changes that occur during ERβ dimerization
and subsequent binding to DNA. This region is highly conserved between ERα and ERβ.
The E domain is the ligand-binding domain (LBD) and the AF-2 region, which is
important for interactions between the dimerized receptors and other transcription factors.
The LBD is comprised of 12 ordered alpha helices, which are integral for ligand
specificity [53]. The true function of the F domain in ERβ remains relatively unknown.
The F domain of ERα is larger than ERβ, and they share about 18% homology, and while
it isn't required for transcriptional activation, it can modulate the activity of ERα [44, 54,
55]. Our laboratory has observed similar effects in human ERβ (hERβ) splice variants
that lack an F domain, but they are still able to activate transcription as measured using
reporter gene assays [56]. Comparatively, rERβ is highly homologous to hERβ, sharing
between 80% homology in the A/B domains and up to 98.5% homology in the C domain
[57].
ERα is derived from a different gene than ERβ, but acts in a similar manner as a
transcriptional regulator of ER-sensitive genes. ERα was the first described ER. Unlike
ERβ, ERα shows little ligand-independent activity, but the AF-1 domain is very active
under ligand stimulation in ERE reporter-gene expression studies when compared to ERβ

	
  

[58]. In the brain, ERα has been shown to play a critical role in regulating reproductive
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neuroendocrine function and sexual behavior [59]. Studies done by Dupont and
colleagues engineered ERα (ERαKO) and ERβ (ERβKO) null mice to elucidate the
relative contribution of each receptor in the reproductive system. These mouse models
revealed that ERαKO female mice are infertile, while ERβKO mice are only subfertile
[60]. However, ERβKO mice suffered from neurological deficits that weren't exhibited in
ERαKO mice. These results are consistent with a lesser distribution of ERα in the brain
that is not as extensive as ERβ, yet prominent in female reproductive organs. An
interesting finding from these ER-null mouse models is they delineated an important
relationship between ERα and ERβ function: when one of these receptors is nonfunctional, the other can compensate for some of the lost function. In many tissues, ERα
and ERβ are co-expressed, suggesting that they can influence each other's action in a
given cell. Indeed, ERβ has been shown to oppose the effects of ERα in some breast
cancer models, yet it can act synergistically on EREs [61, 62].
There also exists a G protein-coupled estrogen receptor GPER (formerly called
GPR30), which mediates non-genomic effects of E2 [63]. Early studies showed that
intrauterine E2 treatment resulted in a rapid increase in intracellular cAMP [64]. Nearly
three decades later there was evidence that E2 stimulated adenylyl cyclase, leading to
second message signaling by calcium (Ca2+) and inositol triphosphate (IP3) [65-68]. The
discovery of GPER led to the novel understanding that E2 not only regulates gene
transcription, but can also regulate important second messenger signaling pathways that
mediate cell growth and survival [69].

	
  

ERβ Distribution in the Brain
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The distribution of ERβ expression in the brain varies according to specific region
and sub-nuclei within those regions [70-72]. For instance, ERβ can be found throughout
the hypothalamus, an important brain region which regulates stress, mood and other
autonomic functions [59]. The hypothalamus also contains several sexually dimorphic
nuclei, meaning that there are clear differences between both structure and function
between males and females [59, 73]. This part of the brain also responds differently to
sex steroid hormones in males and females, which is in part due to differential expression
of ERs in this region. A high density of ERβ expressing cells has been shown in two
particular subnuclei of the hypothalamus, the preoptic area (POA) and paraventricular
nucleus (PVN) [70]. These two regions are important for mediating the release of
neuroendocrine hormones, such as gonadotrophin-releasing hormone (GnRH) and
corticotrophin-releasing hormone (CRH), respectively [74, 75].
Estrogen receptors also play important regulatory roles in learning and memory,
which are processes mediated in large part by the hippocampus; a brain region that
expresses high levels of ERβ [70]. The two major divisions of the hippocampus, the
dorsal and ventral hippocampus, have differing functions. The dorsal hippocampus is
associated with spatial memory, verbal memory, and learning of conceptual information,
while the ventral hippocampus functions in fear conditioning and affective processes [7678]. The importance of E2 in mediating cognitive functions within these regions has been
described through synaptic plasticity and cell proliferation in the hippocampus, and loss

	
  

of E2 signaling can negatively affect these functions as observed in multiple behavioral
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and cellular studies [79-85].
Another important sexually dimorphic region in which ERβ expression is
observed in high density is the amygdala, which performs a primary role in processing of
emotional memories [86]. Divided into four subdivisions (medial, cortical, central and
basolateral), all four of these divisions express ERβ [70]. Anxiety disorders have been
linked to dysfunction of the amygdala, a disorder which is more prevalent in females than
in males [87, 88]. Amygdala dysfunction has been attributed to disrupted connections
with the hypothalamus and cerebellum. Furthermore, analysis of the distribution of ERβ
in the cerebral cortex revealed a high density of ERβ expressing cells within layers IV-V
[70]. Moderate ERβ expression can be found also within layers II-IV. Expression of ERβ
in the cortex has been linked to homeostasis of the cortex, including increased spine
density and modulation of synaptic signaling [89, 90].

ERβ Alternative Splicing
Like many multiexonic proteins, ERβ is subject to alternative splicing. These
alternative splicing events can result in the loss or addition of exons that can alter the
function of the receptor. Shortly after the discovery of ERβ, a second isoform was
discovered from cDNA libraries of rat ovary that encoded a longer form of ERβ [91].
This was quickly followed by the discovery of hERβ splice variants in testis cDNA
libraries [92]. Rat (r)ERβ2 has an 18 amino acid insert within the ligand binding domain
that decreases its affinity for estrogen up to 30-fold [93]. Shortly thereafter brought the

	
  

discovery of additional splice variants in the rat that followed different alternative
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splicing patterns than those observed in humans [94, 95]. The delta variants, delta3 (d3)
and delta4 (d4), result from an exclusion of exon 3 or 4, respectively. A deletion of exon
3 results in the loss of the receptor’s ability to bind DNA, with 39 amino acids deleted
from the DBD. Deletion of exon 4 not only eliminates its ability to bind ligand, but also
alters the cellular localization of the receptor. As observed by Price and colleagues this
variant appears to be abundantly present in the cytoplasm and lacks a nuclear localization
signal [94]. The d3 variant appears to occur independently of ERβ2 alternative splicing
due to the coexistence of both an ERβ1d3 variant and ERβ2d3 variant. The d4 variant
only appears to occur as ERβ1d4, although it's been postulated that ERβ2d4 may also
exist.
By comparison, alternative splicing of human (h)ERβ yields splice variants that
are all truncated by varying lengths at the C-terminus, which eliminates the F domain and
portions of the LBD [92]. In the brain, there are at least 4 splice variants described in
humans and 5 in rat. An additional human splice variant, hERβ3, has also been described
and its expression is restricted to the testis [92].
The expression of the ERβ splice variants occur throughout the brain, and they
tend to be expressed in a region-specific manner [96]. For instance, the PVN and the
supraoptic nucleus (SON) both highly express ERβ splice variants [94, 97]. In addition,
the hippocampus expresses the ERβ2 splice variant along with less observed ERβ1d4
variant [94]. Interestingly, increased expression of the ERβ splice variant ERβ2 has also
been linked to anxiety disorders in female ovariectomized (OVX) rats [79] and studies
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Figure 2. Diagram of rat and human ERβ splice variants. Structural depiction
comparing the differences between rat and human splice variants of ERβ. A/B = AF-1
domain, C = DNA binding domain, D = hinge domain, E = AF-2/ligand binding domain,
F= undefined.

	
  

have confirmed that the amygdala expresses the ERβ2 splice variant, along with
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ERβ1d3 and ERβ2d3 [94]. The cortex also expresses the ERβ splice variants ERβ2 and
ERβ1d3 [94, 95]. Taken together, these brain-region specific patterns of ERβ splice
variant expression suggests that each splice variant has distinct mechanisms regulating
their alternative splicing.
The ERβ splice variants are both structurally and functionally different from the
wild-type ERβ1. Our laboratory revealed that ERβ2 had weaker effects on ERE- and
activator protein (AP)-1-mediated luciferase reporter gene activity in the presence of E2,
and the ERβ-selective agonist diaryl propriolnitrile (DPN), when compared to ERβ1 [98].
Unlike ERβ1, ERβ2 was also unresponsive to the androgen metabolite 5α-Androstane-3β,
17β-diol (3βAdiol), further revealing the effects of alternative splicing on the LBD.
These differential functions were also demonstrated using complex gene promoters, such
as GnRH and arginine vasopressin (AVP). Specifically, ERβ1d3 increased GnRH
promoter activity both in the presence and absence of E2, which differed from the effects
of ERβ1 or any of the other splice variants [99]. Both ERβ1 and ERβ2 increased reporter
activity through ligand-independent actions, but E2 treatment blocked this ligandindependent effect. However, the use of selective estrogen receptor modulator (SERM)
raloxifene inhibited GnRH the promoter E2-dependent increase observed with ERβ1d3.
These opposite effects of treatment on ERβ1d3-mediated transcription suggested that the
structural differences resulting from alternative splicing alters the protein conformation
upon ligand binding. Ligand-induced changes in protein conformation are critical for
exposing docking sites to recruit the necessary coregulatory proteins required for

	
  

mediating transcriptional activity. Thus, the ERβ splice variants might recruit a

17	
  

different suite of coregulatory proteins, or might have decreased ability to form stable
protein:protein interactions, resulting in differential signaling through these alternative
forms of the receptor.
Further studies of the rERβ splice variants, ERβ2 and ERβ1d3, showed that they
were less effective at stimulating AVP promoter activity in the absence of ligand when
compared to ERβ1 [100]. However, ERβ2, but not ERβ1d3, stimulated AVP promoter
activity equally well when treated with either E2 or the ERβ-selective agonist 3βAdiol.
The ERβ1d3 splice variant was shown to have no effect on AVP promoter activation,
either in the presence or absence of ligand binding. The production of a novel ERβ2
antibody by Chung and colleagues increased our understanding of ERβ2 coexpression
with GnRH and oxytocin neurons in the brain, and also expanded the field of ERβ splice
variant studies [101]. A recent study using this ERβ2 antibody showed that increased
ERβ2 protein expression resulted in negative effects on hippocampal neurogenesis and
depressive-like behaviors in aged female rats [79]. These studies also detected ERβ2
protein in white blood cells, uncovering a possible marker for the study of E2 efficacy of
HT in the context of the timing hypothesis. Together, these functional differences
demonstrate that increased expression of ERβ splice variants with age and/or decreased
circulating levels of E2 could have profound impacts on ERβ-mediated gene expression.
Our laboratory has also studied the function of hERβ splice variants using
neuronal cell lines, and have showed that these human variants are able to activate EREregulated promoter activity in a ligand-independent manner similar to rERβ, but are

	
  

largely unresponsive to ligand [56]. Functional studies of hERβ splice variants in the
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brain are prohibitive and we must rely on rat models to provide a basis for their
speculative roles in human. However, studies have used human breast, ovarian, and
prostate cell and tissue models to understand the role of the hERβ splice variant in those
contexts [102-109]. Moreover, 5 additional hERβ disease-related splice variants have
been described in a recent mini-review by Taylor et al. [110].
ERα is also subject to alternative splicing, yet it is relatively unknown if these
splice variants are expressed as proteins [110-112]. To date, 18 splice variants have been
described in the brains of patients who suffered from schizophrenia [113], and more than
20 variants have been found in breast cancer cell lines and tumors [114]. Interestingly, a
recent study found that nuclear protein E3-3 (NPE3-3) regulates alternative splicing of
several of these ERα variants [115]. It is unclear if this nuclear factor regulates ERβ
alternative splicing.

Regulation of Alternative Splicing
Protein diversity is created through the mechanism known as alternative splicing.
Alternative splicing is the process by which exons located within a pre-mRNA transcript
may be excluded from, or included within, the final gene product depending on a number
of factors that influence this post-transcriptional process. These alternatively spliced
transcripts may result in translated proteins that have similar activity to wild-type
proteins, functionally immature proteins, or proteins that have lost critical domains that
are required for proper physiological function. An estimated 90-95% of multiexonic

	
  

proteins undergo alternative splicing from the approximately 20,000 genes encoded
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within the human genome [116]. Alternative splicing should not be confused with general
RNA splicing events that result in wild-type mature mRNA products for translation.
The process by which alternative splicing occurs is via trans-acting factors
binding to cis-regulatory sites on the pre-mRNA [117-119]. Exon and intron splicing
enhancers (ESEs and ISEs, respectively) are RNA sequences that promote the use of a
weak or gene-regulated splice site, mediated by a complex containing serine-rich (SR)
proteins, which can recruit other splicing factors. Exon and intron splicing silencers
(ESSs and ISSs, respectively) are sequences which repress the use of splice site via
recruitment of factors such as heterogeneous nuclear ribonucleoproteins (hnRNPs) that
block spliceosomal assembly at the site [120].
Trans-acting proteins, called small nuclear ribonucleoproteins (snRNPs), form a
complex with small nuclear RNAs (snRNAs) called the spliceosome. The spliceosome
complex is generally responsible for removing the introns from pre-mRNA transcripts in
order to produce mature mRNA for further processing. The snRNPs, designated U1, U2,
U4, U5, and U6, mediate splicing through a succession of enzymatic reactions, along
with assistance from U2 auxiliary factors (U2AF), splicing factor 1 (SF1) and SR
proteins [118, 121].
U1 binds to the 5' intronic GU sequence along with accessory proteins and
enzymes, which is called the spliceosome E complex (Figure 3) [122]. U2 binds to the
branch site, resulting in the hydrolysis of ATP. This step forms the A complex, a critical
step in determining the site at which splicing will occur by defining the intron to be

	
  

removed and the exon to be included. When the U4/U5/U6 trimer complex assembles,
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U5 binds to the 5' exon and U6 binds to U2, forming the B complex [123]. U1 is released
from the complex, initiating a shift whereby U5 moves from exon to intron and U6 binds
to the 5' splice site, which subsequently forms the C complex. U4 is then released and
U6/U2 catalyzes transesterification at the 5' splice site to form the lariat structure at the
branch point [124]. With the U5/U6/U2 complex still bound, the 3' site is cleaved and
ATP hydrolysis drive ligation of the opposing exons. The spliced RNA is then released,
and the remaining spliceosome complex disassembles.
Spliceosome assembly and alternative splicing events are also facilitated by RNAbinding proteins (RBPs). RBPs recognize specific sites located within the pre-mRNA
transcript that can regulate splicing decisions made by the spliceosome, resulting in
alternative splicing events. As mentioned previously, hnRNPs can enhance splice site
silencing through binding of ISS and ESS sequences that can counteract the effects of
other RBPs by blocking their ability to enhance splicing [125, 126]. RBPs are responsible
for a host of interactions that coordinate general RNA splicing. RNA helicases, like
DEAD-Box RNA helicase Ddx17 and Ddx5 are important for altering RNA secondary
sequences, alternative splicing choices, and transcription initiation [127].

	
  

Figure 3. Schematic of spliceosome assembly and RNA splicing (adapted from H.
Urlaub, Max Planck Institute). A generic pre-mRNA transcript is processed by the
spliceosome complex in a highly ordered set of sub-complexes and chemical reactions.
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Other RBPs like RNA binding protein fox-1 (Rbfox1), CUG-Binding Protein
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Elav-like family member (Celf)4, Celf5, and neuro-oncological ventral antigen 1 (Nova1)
are important for development and maintaining splicing patterns in the brain [13, 128131]. Loss or altered expression of these RBPs affect splicing patterns which can affect
synaptic plasticity, neuron excitability, behavior, and development [129, 130].
Alternatively spliced exons can also affect its translation into a protein, and the loss of
these RBPs can result in nonsense-mediated decay (NMD) of the mRNA. NMD allows
the cell to control the translation of mRNAs that would result in a gain of function or
dominant negative form of the protein [132]. However, certain splicing events can result
in mRNA that bypasses the NMD pathway, which results in increased expression of
dominant negative variants.
The alternative splicing of ERβ results in a set of splice variants that can alter the
efficacy of E2-regulated physiological processes. However, the majority of studies have
focused on ERβ splice variants function, and there is little known about the factors
regulating their expression in various tissues [56, 94, 95, 98-100]. The regulatory
mechanisms by which 54bp are inserted into ERβ2, or how exons 3 and 4 are removed
from the pre-mRNA transcripts, along with the possible splicing factors associated with
these alterations have yet to be described. Interestingly, the most commonly studied
splice variant, ERβ2, has sequence characteristics suggesting that it is not a splice variant,
but perhaps is the wild-type form of ERβ. Analysis done in our laboratory of the structure
of ERβ2 shows that the 54bp insert is located within an intron between exons 5 and 6,

	
  

which together comprise the LBD. In order to qualify as an exon, the sequence must be
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present in the mature mRNA and also contains part of the open reading frame (ORF) of
the coded protein [133]. Analysis shows no stop codons that would be read if translation
were out of frame. Further analysis shows weak 5' and 3' splice site upstream and
downstream of the insert (Figure 4) [134, 135]. The regions both contain respective
branch points at which the U2 snRNP may recognize to assist in recruitment of the
U4/U5/U6 trimer. Therefore, these observations suggest that the ERβ2 insert is not an
intronic element, but actually an alternative exon encoded within the pre-mRNA
transcript of ERβ.
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Figure 4. 5’ and 3’ weak splice sites located downstream of Exon 5. Weak splice sites
(underlined text) were detected using SplicePort splice site prediction software
(http://spliceport.cbcb.umd.edu/). The computational donor (5') score was 1.46 and the
acceptor (3') score was 0.851, where a score of 0.8 or greater is considered probable.

	
  

Nova1 Splicing Factor
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Neuro-oncological ventral antigen 1 (Nova1) is a protein that was observed in
patients with paraneoplastic neurological degenerations (PND) to induce an autoimmune
response due to its abnormal expression in tumor cells [136]. It wasn't until after its
discovery as a tumor antigen that continued work done by Darnell and colleagues
elucidated that it was a neuron-specific RNA-binding protein that mediated the
alternative splicing of several receptors in the brain [13, 137]. Nova1 regulates the
expression of many important receptors in the brain, including glycine, GABA, and
dopamine receptors [13, 128, 138, 139]. Studies on RBPs were revolutionized by the
HITS-CLIP method, an UV-crosslink immunoprecipitation experiment for high
throughput studies on RBPs in the brain [140, 141]. These studies were developed by the
same group that discovered Nova1, so naturally the neuron-specific RBP was used for the
development of this method. These studies along with computational analysis led to the
discovery of over 700 splicing events that are regulated by Nova1 in the brain, signifying
the importance of this RBP in neurons [142, 143].
Structurally, Nova1 contains three KH-domains responsible for binding singlestranded RNA [144]. Pre-mRNA transcripts regulated by Nova1 contain a consensus
sequence (YCAY, where Y indicates a pyrimadine) that, when recognized by Nova1,
results in the binding of this protein to the transcript at this location [128]. For efficient
Nova1 binding, these YCAY consensus sequences need to be clustered together.
Therefore, YCAY clusters located in an intron or exon dictates the outcome of splicing of

	
  

the Nova1-regulated mRNA. Intronic YCAY clusters located either upstream or
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downstream of the Nova1 alternatively spliced exon mediate enhanced spliceosome
assembly and inclusion of the exon (Figure 5) [145]. However, intronic YCAY clusters
located immediately upstream of the exon blocked U1 snRNP binding, resulting in exon
exclusion. This was also true for YCAY cluster found within the alternatively spliced
exon itself. However, recent evidence from Park and colleagues found that Nova1
binding to exonic YCAY clusters can block binding of hnRNP M, a known splicing
inhibitor [139]. Degrees by which Nova1 binds these YCAY cluster may lead to a
modulatory or fine-tuning mechanism that coincides with its ability to enhance or repress
alternative splicing. Analysis of ERβ pre-mRNA transcripts show that several YCAY
clusters are located upstream of the ERβ2 insert (Figure 6). Therefore, Nova1 may be an
important regulator of ERβ alternative splicing.
Since the discovery of Nova1 nearly two decades ago, there have been several
studies on the regulation of this splicing factor. One of the first studies on Nova1
expression revealed that Nova1 can autoregulate itself through removing the E4 exon that
contains a phosphorylation domain and KH domain that recognizes the YCAY repeats
[146]. Nova1 expression has been shown to be regulated by hormones like
glucocorticoids (GC) and also by miRNA 181b-5p in the context of astrocytomas [147,
148]. A recent study on aging in the brain revealed Nova1 expression declining with
advanced age, both in healthy and neurodegenerative male patients [149]. These
decreases in Nova1 expression resulted in significant increases in alternative splicing
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Figure 5. A simplified model of Nova1 exon exclusion mechanism. Nova1 recognizes
YCAY consensus sequence located within the intron upstream of an exon. Upon binding,
Nova1 enhances spliceosomal removal of the exon, along with the flanking intronic
element. The excluded elements are removed from the mRNA transcript through RNA
splicing outlined in Figure 3.

	
  

events in proteins associated with neurodegeneration. To date, there have been no
studies determining the effects E2 on Nova1 expression.
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Figure 6. Nova1 consensus sequences in ERβ exon 5. Full-length ERβ mRNA was
analyzed for the presence of Nova1 YCAY consensus sequences using RBPmap
(http://rbpmap.technion.ac.il/index.html). Highlighted (black boxes, white text) regions
indicate consensus YCAY sequences located in the depicted exon 5 (highlighted in dark
gray). The ERβ2 alternatively spliced insert is highlighted in light gray box. Scores
assigned to Nova1-binding probabilities must be greater than 0.895 (out of 1.00) based on
weighted rank in order to be detected (Paz et al., Nucleic Acids Res. 2010).

	
  

CHAPTER III
AGING AND LOSS OF CIRCULATING 17Β-ESTRADIOL ALTERS THE
ALTERNATIVE SPLICING OF ERΒ IN THE FEMALE RAT BRAIN
Endocrinology, 2015 Aug 21:en20151514
Hormone replacement therapy (HT) has become routine in abrogating the
negative effects associated with the decline in circulating 17β-estradiol (E2) in women
postmenopause. The efficacy of HT in mediating these negative effects is temporally
dependent, as inferred from data obtained in the Women’s Health Initiative (WHI) and
Women’s Health Initiative Memory Study (WHIMS) studies. Specifically, HT was
beneficial or neutral for most parameters measured (cognition, memory, cardiovascular)
in younger postmenopausal women, whereas older women, 10 or more years
postmenopause, experienced adverse effects including cardiovascular and coronary
disease, stroke, cognitive impairment, and dementia [2-5, 150, 151]. Other studies have
suggested the idea of a therapeutic window in which HT is beneficial, known as the
“timing hypothesis”, pointing to age-related adjustments that occur during and after this
critical period of declining E2 levels [6, 7, 10-12, 38-41]. Although the benefits of HT on
mood in postmenopausal women are controversial, recent studies have yielded optimism
about the beneficial effects of HT, especially on mood and anxiety [8, 32, 152, 153].
However, the mechanisms by which the molecular environment of the aging brain
changes during this period in response to E2 withdrawal remain unknown. We
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hypothesized that differential effects of E2 could be due to changes in alternative
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splicing of the estrogen receptor.
The physiological effects of E2 are mediated primarily through estrogen receptor
α (ERα) and β (ERβ). These receptors act as transcriptional regulators for genes that are
functionally important for a variety of processes in the brain including memory,
reproduction, and stress [20, 24, 33, 35, 59, 154, 155]. Similar to many other proteins,
ERβ is subject to posttranscriptional alternative splicing. There are several identified ERβ
splice variants that naturally occur in both humans and in rodents [91, 92, 94, 95, 156].
ERβ1 is the wild-type isoform that is primarily expressed throughout the human (hERβ1)
and rat (rERβ1) brain. This isoform also has the highest affinity for E2, the major
circulating estrogen during the reproductively competent period of the lifespan [157]. At
least four hERβ splice variants are expressed in the human brain, and five splice variants
of rERβ have been described in the rat brain [95, 158]. The physiological relevance of
these ERβ splice variants has been highlighted in a recent study where increased
expression of the rat dominant negative ERβ2 isoform diminished the effectiveness of
HT in OVX female rats [79]. This study also revealed that withdrawal of E2 over time
might increase the expression of ERβ2, further implicating the actions of these receptors
when circulating E2 levels reach the nadir that occurs with menopause. Thus, the increase
in alternative splicing of ERβ may negatively impact E2-regulation of important
processes due to the structural and functional differences that occur in these variants.
Alternative splicing of ERβ in humans differs from that in rats: hERβ variants are
the result of truncations from the C-terminal end of the mRNA transcript, while rERβ

	
  

splice variants arise from insertions and deletions within the mRNA transcript (Figure
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2) [92, 94, 95]. Nevertheless, both human and rodent ER variants are functionally
different from the wild-type, can form heterodimers with the wild-type, and ultimately
alter downstream E2-mediated signaling pathways [46, 56, 100, 158]. More importantly,
these splice variants have also been shown by our laboratory to be constitutively active in
the absence of ligand binding, suggesting they might be particularly important
postmenopause. Ligand-independent effects of ERβ impact a variety of genes that are
regulated by ERs, including arginine vasopressin (AVP) and corticotrophin releasing
hormone (CRH) [56, 98, 100, 159], two hypothalamic hormones important for regulating
stress and anxiety [160]. As it pertains to memory, the dorsal and ventral hippocampus
are important regions that also express ERβ splice variants. The dorsal hippocampus is
important for spatial and verbal memory, while the ventral hippocampus is important for
fear conditioning and affective processes [161]. Memory impairment, overall declines in
cognitive function, and increased anxiety are all possible negative effects that coincide
with loss of circulating E2 in postmenopausal women [2, 3, 8, 19, 20, 162]. Therefore
expression of these alternatively spliced receptors during menopause, a time when E2 is
no longer being produced endogenously by the ovaries, may have a variety of
implications within many different brain regions, including the hypothalamus and
hippocampus.
Alternative gene splicing contributes to increased biodiversity of proteins that can
be expressed from a limited set of genes within our genome, as over 95% of multi-exonic
genes are alternatively spliced [116]. Recent evidence has suggested that alternative

	
  

splicing events increase with age in the brain [149]. Gene transcripts that contain
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multiple coding exons can undergo splicing that may exclude these exonic sequences
from the final mRNA transcript to be translated [119]. These alternative splicing events
occur through mechanisms that involve either cis-sequences encoded within the premRNA transcript, or by trans-acting splicing factors, such as RNA binding proteins [163,
164]. The rate at which alternative splicing occurs can also influence exon inclusion
events [165, 166]. For instance, interference of RNA Polymerase II (RNAPII) elongation
rates resulted in inhibition-dependent changes in alternative splicing, whereby exons that
were located 3’ downstream of short intronic sequence were included within the mature
mRNA transcript [167]. It is becoming widely accepted that alternative splicing events
likely occur at the site of transcription, and in cooperation with transcription, and that
these coordinated actions between trans-acting factors and RNAPII are heavily involved
in determining the fate of pre-mRNA transcripts [168, 169].
The purpose of this study was to determine how E2 deprivation, as occurs during
menopause, affects the alternative splicing of ERβ in the aging brain. We hypothesized
that ERβ2 expression would increase in a tissue-specific manner due to age-related and
E2 deprivation-related changes in alternative splicing, and treatment with E2 would
abrogate these effects. To test this hypothesis, we OVX Fisher344 rats at 3 and 18
months of age to study the effects of aging (1 week OVX) and E2 deprivation (1-12
weeks OVX) followed by acute E2 treatment in these animals (Figure 7). Moreover,
changes in the expression or activity of RNAPII have not been previously demonstrated
in aged animals, or in relation to E2 treatment. Therefore, we also assessed expression of

	
  

RNAPII and its activity in these animals to determine how this ubiquitous enzyme

34	
  

might influence alternative splicing. Lastly, we assessed how RNAPII interference may
specifically affect ERβ2 alternative splicing in a hypothalamic neuronal cell line. Our
data revealed that alternative splicing events are influenced by aging and E2 deprivation
in a brain region-specific manner. We also observed that interference of RNAPII
increased expression of ERβ2, and that expression and activity of RNAPII changes with
aging and E2 deprivation in a brain region-specific manner.
Briefly, 3 and 18 month old animals underwent OVX and subjected to our E2
deprivation paradigm and then treated with vehicle or E2 (Figure 7). Circulating E2
concentration was measured in blood to determine levels of hormone prior to studies. A
separate group of 18 mo. animals were treated with ERα and ERβ-selective agonists. To
determine the effects of aging and E2 deprivation on ERβ alternative splicing, total ERβ
and ERβ2 mRNA expression were measured in the hypothalamus, dorsal hippocampus,
and ventral hippocampus of these animals. A set of intact animals were used to compare
expression levels of ERβ in the hypothalamus. An in vitro set of studies were conducted
in hypothalamic neurons treated with the TOPI inhibitor camptothecin, E2, or a
combination of both to determine the effects of splicing kinetics on ERβ alternative
splicing. To determine if aging and E2 deprivation had an effect on RNAPII, expression
and activity of RNAPII were measured in the 18+ mo. animals subjected to the
deprivation paradigm only via qRT-PCR and western blot.
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Figure 7. Diagram of the E2 deprivation paradigm. Animals were ovariectomized at
day 0 and then separated into 4 deprivation groups (N=16-20/deprivation group) that
were subjected to increasingly longer periods of hormone deprivation (1, 4, 8, and 12
weeks). Following deprivation, animals were treated with either vehicle (safflower oil) or
E2 (2.5 µg/kg) by subcutaneous injection once daily for 3 consecutive days (n=610/treatment group). Animals were sacrificed 24 hours following the last treatment.
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ERβ alternative splicing in the aging brain
No changes in total ERβ or ERβ2 expression were detected in ovarian intact
animals whose ages corresponded with either 3-mo. old OVX animals, or 18-mo. old
OVX subjected to the E2 deprivation paradigm (Figure 8D). There was a significant
decrease in total ERβ expression between the 3-mo. and 18-mo. intact animals.
Comparison of 3-mo. vs. 18-mo. OVX animals treated with vehicle or E2 revealed a
statistically significant main effect of age (F(1,18)=7.838, p<0.015) on ERβ2 expression
in the hypothalamus (Fig. 9A, hatched region), but not the dorsal or ventral hippocampus
(Fig. 9B,C). In the hypothalamus, ERβ2 expression was not affected by E2 treatment in
3-mo old animals (Fig. 9A). By contrast, ERβ2 expression was significantly decreased in
18-mo. old vehicle-treated animals compared to 3-mo old animals, yet it was significantly
increased following E2 treatment. Further, E2 treatment significantly decreased total ERβ
expression only in the dorsal hippocampus and there were no differences in 18-mo. old
animals between treatment groups (Fig. 9B). The other previously identified rat ERβ
splice variants, ERβ1d3, ERβ1d4, and ERβ2d3, were undetectable in either age group for
all brain regions tested (data not shown).
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Figure 8. Vaginal cytology, E2 plasma concentrations, and alternative splicing of
ERβ in intact animals. (A) Representative image (20x) from vaginal smears that were
obtained from 18-mo. old female rats daily for seven days before OVX (N = 6). Cells
were stained with Papanicolaou stain before imaging. Orange G (orange) stains
keratinized squamous epithelial cells. Eosin azure (blue) staining cells represent nonkeratinized squamous epithelial cells, neutrophils, and red blood cells (if present). (B)
Concentration (pg/ml) of plasma E2 in vehicle- and E2-treated animals during hormone
deprivation paradigm. E2 concentration was analyzed by 17β-Estradiol high sensitivity
ELISA Kit. 18-mo. animals prior to OVX had low circulating E2 levels (35.0 ± 7.1
pg/ml, N = 6). (C) Total ERβ (white region) and ERβ2 (hatched region) mRNA
expression was measured in the hypothalamus of intact (non-OVX) 3 and (D) 18-21
month old female rats. a, indicates statistically significant difference (p< 0.05) between
groups as determined by paired t-test. Data are expressed as mean ± SEM.
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Figure 9. Comparison of total ERβ and the fraction that represents ERβ2 (hatched
region) mRNA expression in the young and aged female rat brain. ERβ2 expression
was measured in the (A) hypothalamus, (B) dorsal hippocampus, and (C) ventral
hippocampus at 1 week post-OVX in 3 and 18-mo. old female rats (N = 6/age/treatment
group). Animals were OVX and 1 week later treated with either vehicle (safflower oil) or
2.5 µg E2 (dissolved in safflower oil). The letter “a” indicates a statistically significant
difference (p< 0.05) in total ERβ and the letter “b” indicates a statistically significant
difference (p< 0.05) in ERβ2 as determined by Tukey’s Honestly-Significant-Difference
Test following two-way ANOVA. Data are expressed as mean ± SEM.
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Brain region-specific changes in ERβ splice variant expression following varying lengths
of E2 deprivation in aged female rats
To assess the effects of varying lengths of E2 deprivation in the aged brain, 18mo. old animals were OVX followed by administration of vehicle or 2.5 ug/kg E2
once/day x 3 consecutive days at varying time points (Fig. 7). Two-way ANOVA
revealed a significant interaction between the length of E2 deprivation and subsequent E2
treatment in the hypothalamus (F(3,40)=3.943, p<0.015) (Fig. 10A). There was also a
significant main effect of length of E2 deprivation alone (i.e. vehicle treatment) on ERβ2
expression in both the dorsal and ventral hippocampus (F(3,42)=7.714, p<0.001 &
F(3,41)=8.409, p<0.001, respectively) (Fig. 10, B and C), as well as a significant main
effect of treatment in the dorsal hippocampus (F(1,42)=5.115, p<0.05) (Fig. 10B),
although no statistically significant interaction was revealed in these brain regions.
Treatment with E2 significantly increased ERβ2 at the one-week deprivation time point
in the hypothalamus (Fig. 10A), consistent with our earlier-described experiment
comparing 3-mo and 18-mo. animals (Fig. 9A). E2 treatment also significantly increased
ERβ2 expression in the hypothalamus at 12, but not 4 or 8 weeks deprivation (Fig. 10A).
Analysis of total ERβ expression revealed a significant interaction between E2
deprivation and subsequent E2 treatment in both the dorsal and ventral hippocampus
(F(3,42)=12.932, p<0.001 & F(3,41)=33.585, p<0.001, respectively) (Fig. 10, B and C).
In addition, a significant main effect of E2 treatment on total ERβ expression was
observed in the hypothalamus (F(1,40)=6.378, p<0.016). Significant increases in total
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Figure 10. Expression of total ERβ and ERβ2 mRNA in the brain of aged (18-mo.
old) female rats following varying periods of E2 deprivation. ERβ2 mRNA expression
was measured in the (A) hypothalamus, (B) dorsal hippocampus, and (C) ventral
hippocampus at 1, 4, 8, and 12 weeks post-OVX (N = 6-10/age/treatment group).
Animals were treated with either vehicle (safflower oil) or 2.5 µg E2 (dissolved in
safflower oil). The letter “a” indicates a statistically significant difference (p< 0.05) in
total ERβ and the letter “b” indicates a statistically significant difference (p< 0.05) in
ERβ2 as determined by Tukey’s Honestly-Significant-Difference Test following two-way
ANOVA. Data are expressed as mean ± SEM.

	
  

ERβ expression with treatment mirrored the pattern observed for ERβ2 expression at 1
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and 12 weeks deprivation (Fig. 10A). We observed a significant decrease in ERβ2
expression in both the dorsal and ventral hippocampus following E2 treatment at 4
weeks, but expression levels returned to baseline (i.e. one-week post OVX) beyond this
time point (Fig. 10, B and C). Total ERβ expression, on the other hand, decreased after 4
weeks deprivation in both dorsal and ventral hippocampus, and remained lowly expressed
through the remainder of the deprivation paradigm, whereas administration of E2 at 4
weeks in the ventral hippocampus resulted in a significant increase in total ERβ
expression (Fig. 10C).

E2-induced increases in alternative ERβ splice variant expression is mediated
primarily by ERβ
The effects mediated by E2 on ERβ alternative splicing could be mediated by
either ERα or ERβ, as both are expressed in each of the brain regions tested [70]. To
determine which E2 receptor mediated observed increases in ERβ2, acute administration
of the ERβ-specific agonist diarylproprionitrile (DPN) or the ERα-specific agonist propyl
pyrazole triol (PPT) was given to 18-mo. old female OVX rats. Our results demonstrated
that DPN, but not PPT, significantly increased expression of ERβ2 (Fig. 11).
Administration of E2, DPN or PPT significantly increased total ERβ as observed
previously.
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Figure 11. The ERβ-selective agonist DPN increases ERβ alternative splicing. (A)
Total ERβ and ERβ2 (hatched region ) mRNA expression was measured in the
hypothalamus of aged female rats that were OVX and 1 week later treated with either
vehicle, E2, 1mg/kg DPN, or 0.5 mg/kg PPT once/day for three consecutive days (N = 68/treatment group). The letter “a” indicates a statistically significant difference (p< 0.05)
in total ERβ and the letter “b” indicates a statistically significant difference (p< 0.05) in
ERβ2 as determined by Tukey’s Honestly-Significant-Difference Test following one-way
ANOVA. Data are expressed as mean ± SEM.

	
  

Altering splicing kinetics increases ERβ2 expression
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The insertion of 54 base pairs (bp) that encode the rERβ2 splice variant are
located within the intron between exons 5 and 6, which together encode the ligandbinding domain of ERβ (Fig. 2). Inhibition of topoisomerase I (TOP1) can slow down
splicing kinetics, resulting in exon inclusion by allowing the spliceosome machinery
more time to recognize weak splice sites in shorter intronic elements flanking the exon
[166, 167], yet exons flanked by longer intronic sequences are generally excluded despite
TOP1 inhibition. Interestingly, the putative sequence upstream of the ERβ2 insertion is
much shorter than most intronic elements in the ERβ pre-mRNA transcript (841 bp
compared to the next shortest sequence which is greater than 1K bp). To test if ERβ2
alternative splicing increases with slower splicing kinetics through TOP1 inhibition, we
used hypothalamic-derived neuronal cells (GT1-7). Cells were treated with the TOP1
inhibitor camptothecin (32 ng/µl) in the presence or absence of E2 following a period of
steroid hormone deprivation. Our results also revealed a significant main effect of
treatment (F(3,12=3.544, p<0.05) on ERβ2 expression. Specifically, inhibition of TOP1
significantly increased ERβ2 expression and co-treatment with E2 blocked this effect
(Fig. 12).
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Figure 12. Camptothecin treatment in hypothalamic GT1-7 cells increases ERβ2
expression. ERβ2 mRNA expression was measured in the GT1-7 cell line following 6
hour treatment with 32 ng/ul camptothecin or camptothecin + 10 nM E2 or vehicle
(DMSO) (N = 3). *, indicate statistically significant difference (p< 0.05) from 1 week
vehicle-treated animals as determined by Tukey’s Honestly-Significant-Difference Test
following one-way ANOVA. Data are expressed as mean ± SEM.

	
  

Brain region-specific changes in RNA Polymerase II in aged female rats
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We hypothesized that increased RNAPII expression and/or activity would be
coincident with our observed increases in age-related alternative splicing of ERβ. Our
results revealed a statistically significant interaction between age and treatment in the
hypothalamus (F(1,18)=8.317, p<0.01) (Fig. 13A), but not in the dorsal or ventral
hippocampus (Fig. 13B, C). Further, E2 treatment increased RNAPII mRNA expression
in the 3-mo. animals, whereas neither age nor E2 affected RNAPII mRNA expression in
the 18-mo. animals. A significant main effect of age on RNAPII expression was observed
in the dorsal hippocampus (F(1,18)=4.825, p<0.05) (Fig. 13B), which was further
increased by E2 treatment in aged, but not young, animals (Fig. 13B).
Aged animals subjected to our E2 deprivation paradigm showed a statistically
significant main effect of E2 deprivation alone (i.e. vehicle treatment) and a main effect
of subsequent E2 treatment on RNAPII expression in the hypothalamus (F(3,40)=4.591,
p<0.01 & F=(1,40)8.504, p<0.01, respectively) and dorsal hippocampus (F(3,44)=3.541,
p<0.05 & F(1,44)=4.222, p<0.05, respectively) (Fig. 13D, E). Conversely, in the ventral
hippocampus there was a significant main effect of deprivation alone (F(3,42)=6.316,
p<0.001), but not E2 treatment (Fig. 13F). In the dorsal hippocampus, E2 treatment
significantly increased RNAPII expression at 1-week deprivation only (Fig. 13E). E2
treatment resulted in a significant decrease of RNAPII in the ventral hippocampus of
animals deprived of E2 for 12 weeks (Fig. 13F) with or without E2 treatment.
Next, we measured RNAPII activity using western blot by probing for
phosphorylated RNAPII (p-RNAPII) and comparing these levels to total RNAPII protein

	
  

expression in the animal paradigm described previously. The data revealed a
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significant main effect of deprivation in all three brain regions (F(3,40)=3.634, p<0.05,
hypothalamus; F(3,44)=4.467, p<0.01, dorsal hippocampus; F(3,42)=3.341, p<0.05,
ventral hippocampus) (Fig. 14). In the hypothalamus, there was a significant difference
between the 1-week and 8-week vehicle-treated animals, as p-RNAPII expression was
nearly undetectable at the 1-week time point for both vehicle- and E2-treated animals
(Fig. 14A, B). The ventral hippocampus had a significant decrease in p-RNAPII
expression following treatment with E2 at 12-weeks when compared to the vehicletreated animals at the same time point (Fig. 14E, F).
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Figure 13. Effects of age and varying periods of E2 deprivation on RNA polymerase
II mRNA expression in the brain of young and aged female rats. RNAPII expression
was measured in the (A) hypothalamus, (B) dorsal hippocampus, and (C) ventral
hippocampus at 1 week post-OVX in 3 and 18-mo. old animals (N = 6/age/treatment
group). RNAPII expression was also measured in the (D) hypothalamus, (E) dorsal
hippocampus, and (F) ventral hippocampus at 1, 4, 8, and 12 weeks post-OVX (N = 610/age/treatment group). Animals were treated with either vehicle (safflower oil) or 2.5
µg E2 (dissolved in safflower oil). An * indicates a statistically significant difference (p<
0.05) between groups and # indicates a statistically significant within groups as
determined by Tukey’s Honestly-Significant-Difference Test following two-way
ANOVA. Data are expressed as mean ± SEM.
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Figure 14. Effects of varying periods of E2 deprivation on RNA Polymerase II
activity in aged female rats. Phosphorylated RNAPII and total RNAPII protein levels
were measured by western blot in the (A, B) hypothalamus, (C, D) dorsal hippocampus,
and (E, F) ventral hippocampus at 1, 4, 8, and 12 weeks post-OVX (N = 610/age/treatment group). Following E2 deprivation, animals were treated with either
vehicle (safflower oil) or 2.5 µg E2 (dissolved in safflower oil). An * indicates a
statistically significant difference (p< 0.05) between groups and # indicates a statistically
significant within groups as determined by Tukey’s Honestly-Significant-Difference Test
following two-way ANOVA. Representative blot images combined from several western
blots used to quantify protein expression.
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This study presents a detailed analysis of the alternatively spliced ERβ variant,
ERβ2, in the hypothalamus, dorsal hippocampus, and ventral hippocampus with regards
to aging and E2 deprivation in young animals, and in an aged surgically-induced
menopausal animal model designed to mimic E2 replacement therapy occurring at
varying time points following menopause. Our studies demonstrate the novel findings
that age and E2 deprivation affect ERβ alternative splicing in a brain region-specific
manner. The brain regions analyzed all express ERβ2, as previously shown through
immunocytochemistry using an ERβ2-specific antibody, and E2 signaling is
physiologically important in these regions for mediating stress responses or enhancing
memory through neurogenesis and synaptic plasticity [79, 100, 101, 170, 171].
Importantly, we also report the first evidence for a putative molecular mechanism
regulating alternative splicing of ERβ in the brain, although these data are cautiously
interpreted and more mechanistic studies are required to validate a causal relationship.
Specifically, these data reveal that the E2-induced alternative splicing of ERβ may be
mediated by actions through its own receptor and through changes in splicing kinetics.
Indeed, the inclusion of the ERβ2 insert that results in the dominant negative phenotype
of the receptor can be increased by inhibiting TOP1, which suggests that the 18AA ERβ2
“insert” in the ligand binding domain might actually be considered an exon [133, 166,
167]. We also demonstrate a putative molecular mechanism for age-related changes in
alternative splicing through our observations that age and E2 treatment alter RNAPII
mRNA expression and activity. Age-dependent changes in RNAPII mRNA expression

	
  

levels and/or enzymatic activity might have implications on global alternative splicing
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patterns where E2 could play a key regulatory role. Taken together, these data contribute
to our overall understanding of ERβ alternative splicing in the aging female brain.
We used a surgically induced menopause and E2 replacement paradigm to
address the hypothesis that aging and/or long periods of ovarian hormone deprivation
alters the expression of alternatively spliced ERβ variants, which could provide a
mechanistic explanation for decreased E2 efficacy in older women. Specifically, ERβ2
has been shown to antagonize the actions of ERβ1 and has a much lower binding affinity
for E2; both of these factors could decrease the efficacy of E2 replacement therapy
following menopause. We were able to achieve clinically relevant levels of E2 following
administration in our female OVX rats that were similar to those observed in
postmenopausal patients that received hormone replacement therapy [34, 172].
Interestingly, E2 administration had brain region-specific effects between the
hypothalamus and hippocampus: treatment in the hypothalamus resulted in significant
increases in ERβ alternative splicing, whereas treatment in the dorsal and ventral
hippocampus resulted in significant decreases. The significant increases in the
hypothalamus of ERβ2 following E2 treatment also corresponded with significant
increases in total ERβ expression. Therefore, increased availability of ERβ pre-mRNA
due to increased transcription could allow for increased alternative splicing through
cotranscriptional events [165, 169]. These data suggest that any assessments of E2
efficacy will differ depending on the physiological endpoint measured, because each of
these brain regions regulates distinct physiological functions. In particular, gene

	
  

expression within the hypothalamus has recently been shown to adapt to changes in
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circulating E2 levels, and the increase observed in ERβ2 expression, along with its ability
to act in a ligand-independent manner, may underlie this neuronal adaptation to
fluctuating circulating E2 levels throughout the lifespan [56, 100, 173]. Another
important recent study investigated E2 deprivation of 9 mo. old animals given E2
treatment either 6 or 180 days (i.e. 15 mo. old) post-OVX using Sprague-Dawley rats.
They demonstrated a decrease in E2 efficacy on hippocampal neurogenesis and
neuroprotection that coincided with increased expression levels of ERβ2, suggesting that
ERβ2 was responsible for the observed decreased E2 efficacy [79]. Our data suggest that
aged Fisher344 rats this increase in ERβ2 does not persist in the hippocampus, but
instead becomes much more evident in the hypothalamus, a brain region with direct
anatomical connections to the hippocampus. Wang and colleagues also showed that E2
treatment blocked the observed increase in ERβ2 expression in animals that were
deprived of E2 for only 6 days, but E2 was ineffective following 180 days post-OVX
[79]. Our results are consistent with these, as we also did not observe a significant effect
of E2 following longer periods of E2 deprivation (>8 weeks). Collectively, these data and
those from previous studies suggest that ERβ2 is the predominant variant expressed in the
hippocampus and hypothalamus as the time of E2 deprivation lengthens [19, 174, 175].
Future studies into specific hypothalamic nuclei and hippocampal subgroups may further
reveal finite brain-region specific changes occurring during E2 deprivation.
We have shown that E2 can regulate ERβ alternative splicing in a brain regionspecific manner, however whether E2 was acting through ERα or ERβ was unclear.

	
  

Previous studies have shown age-related changes in the expression levels of ERα
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within these specific brain regions, whereas there are conflicting reports regarding the
expression of ERβ [70, 176, 177]. These data led us to predict that E2 effects in aged
animals would most likely be mediated by ERβ or ERα. Indeed, treatment with the ERβselective agonist DPN resulted in a significant increase of ERβ alternative splicing,
whereas treatment with the ERα-selective agonist PPT had no effect on splice variant
expression however, it may be possible that ERα may be mediating increases in total ERβ
in coordination with ERβ, as shown in the PPT-treated animals. It is possible that the lack
of a PPT effect is reflective of altered expression levels of ERα in aged animals; therefore
we are unable exclude the possibility that ERα could mediate E2-induced alternative
splicing in younger animals.
To our knowledge, no studies to date have investigated the mechanisms regulating
ERβ alternative splicing in the brain or any other tissue. In these studies, we investigated
two potential mechanisms to explain age-related changes in alternative splicing of ERβ.
First, taking advantage of a novel compound called camptothecin, a TOP1 inhibitor, we
tested the idea that the weak splice site near the short, 54bp intronic sequence of ERβ2
would increase if transcription kinetics were slowed. Camptothecin has been used
previously in several studies to investigate how the rate of transcription can affect
alternative splicing [167, 178]. Therefore, we treated hypothalamic-derived GT1-7 cells,
which express ERβ2, with camptothecin and observed a statistically significant increase
in ERβ2 expression. Contrary to what we predicted based on the data obtained in vivo in
our aged animals, concomitant E2 and camptothecin treatment attenuated the observed

	
  

increase in ERβ alternative splicing. These data suggest that E2 might be able to
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overcome RNAPII stalling, whether by upregulating expression of RNAPII to
compensate for the stalled enzymes or increasing activation of other RNAPII present via
phosphorylation, however further experiments are required to validate this mechanism.
The kinetics of gene transcription is largely dependent on the activity of RNAPII.
Given that a slower rate of transcription promoted increased inclusion of a unique
sequence, thereby increasing expression of ERβ2, we tested if RNAPII mRNA
expression was affected either by age, loss of circulating E2, or both. Our results
demonstrated that RNAPII mRNA increased with age in the hypothalamus, which
correlated with a decrease in ERβ2 expression that was previously observed. Moreover,
E2 treatment also increased RNAPII expression in an age and tissue-specific manner, but
expression of this enzyme may require distinct splicing factors, which may or may not be
altered by age, E2, and brain region. One putative candidate is the CNS-specific splicing
factor Nova1, as it has been previously shown to decrease in the brain with age [149],
however no studies to date have made a direct link between ERβ and any splicing factor.
Investigation of each deprivation time point in which these changes occur could provide
more insight into which splicing factors could be involved, and our observed correlative
results may also provide insight into mechanistic explanations for the timing hypothesis
of hormone replacement therapy efficacy that need to be further investigated.
Our model, along with the previous studies outlined in this manuscript, raise
important limitations to consider. The model we used to study menopause and the timing
hypothesis differ in some aspects with other similar studies [79, 173]. Importantly,

	
  

rodents do not undergo a menopausal transition that is similar to humans and,
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therefore, most studies have relied on using a surgically-induced menopause model, or a
chemically-induced delayed depletion of ovarian follicles. Chemically induced ovarian
failure, as reported previously, is a valuable model to study the menopausal transition,
however in these studies we chose the surgical model in order to precisely measure the
length of time following complete ovarian E2 deprivation [179]. In addition, there is
some debate regarding the correct age in rodents to begin manipulations so that they will
provide a good comparison to the human menopausal condition and yield generalizable
results. These discrepancies are likely related to strain-specific differences in rats and this
is a very important consideration when comparing various reports in the literature. For
instance, Sprague-Dawley rats have an average cycle cessation at 8-12 months, whereas
the Fisher344 rat strain undergoes cycle cessation at 16-18 months [180, 181]. Also, the
predominant postcyclic vaginal state in Sprague-Dawley rats is persistent estrous,
resulting in high estrogen levels. Fisher344 by contrast typically exhibit repeated
pseudopregnancy with low estrogen, but higher progesterone [182]. Utilizing previously
reported data on aging in Fischer 344 rats, we were able to correlate an approximate age
of our animals with a human age (an 18-mo. old rat equals a 55 year old human [180183]. Interestingly, a recent study by Yin and colleagues, also using the surgicallyinduced menopause rat model, demonstrated that changes in the brain occur well before
the onset of menopause and that hypothalamic neuronal networks are highly adaptable to
fluctuations in circulating E2 levels [173]. We propose that this adaptability could be the

	
  

result of altered alternative ERβ splicing and subsequent changes in the ratio of
alternatively spliced ERβ isoforms.
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CHAPTER IV
AGING AND LOSS OF CIRCULATING 17Β-ESTRADIOL ALTERS THE
EXPRESSION OF NOVA1, A REGULATOR OF ERβ ALTERNATIVE SPLICING
Introduction
Alternative splicing contributes to increased biodiversity of proteins that can be
translated from the limited set of genes within eukaryotes. It is estimated that over 95%
of multi-exonic genes are alternatively spliced [116]. At the center of this, RNA-binding
proteins (RBPs) fundamentally regulate post-transcriptional alternative splicing. These
trans-acting factors bind to cis-sequences contained within the pre-mRNA transcript to
coordinate and facilitate alternative splicing events. RNA binding proteins not only
regulate pre-mRNA splicing, but also coordinate 5' end capping, cleavage,
polyadenylation, nuclear mRNA export, localization, translation, and degradation of
mRNA [164]. These critical RNA binding proteins can also be tissue-specific, which is
evidenced by the disproportionately high number of alternative splicing events that occur
in the brain [118, 184].
Recent evidence has suggested that alternative splicing increases in the brain with
age [149]. These studies found that the CNS-specific splicing factor Nova1 decreased
with age while alternative splicing events in several proteins increased concomitantly
[149]. Increases in alternative splicing events can have negative implications on disease
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and neurodegeneration due to variant function in the brain [185, 186]. Nova1 is a
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RNA-binding protein that binds YCAY elements coded in pre-mRNA transcripts to
enhance or block exon exclusion in a location-dependent manner [143, 145]. Nova1, like
many RNA binding proteins, work in concert with hnRNPs, SR proteins, and other
factors to regulate splicing [187].
To further compound the effects of aging is the menopausal transition and the
associated decline in circulating estrogens, more specifically 17β-estradiol (E2), the
major estrogen produced by the ovaries. E2 mediates its actions through two important
nuclear steroid receptors in the brain called estrogen receptor (ER) α and ERβ. In the
classical model of nuclear receptor action, these ERs bind ligand, dimerize, and
translocate to the nucleus, where they mediate E2-regulated gene transcription [43]. Our
laboratory has recently shown that age and increased lengths of E2 deprivation can alter
the mRNA expression of alternatively spliced ERβ in a brain region-specific manner
[96]. Those studies showed age-related increases in ERβ2 mRNA expression, which is a
dominant negative form of the receptor that is unable to bind E2 efficiently due to a
spliced insert within the ligand-binding domain (LBD). Others have also observed an
increase in ERβ2 protein levels following prolonged periods of E2 deprivation [79]. The
efficacy of hormone replacement therapy (HT) may depend on the expression of these
splice variants due to their inability to mediate normal E2 signaling in the cell [46, 56,
100, 158]. Interestingly, the ERβ pre-mRNA transcript contains several Nova1 RBP
consensus sequences upstream of the ERβ2 insert that may promote exon inclusion or

	
  

exclusion based on their location (Figure 6). Therefore, it is possible that Nova1 can
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regulate ERβ alternative splicing through RBP interactions post-transcriptionally.
The purpose of this study was to determine how aging and E2 deprivation, as
occurs during menopause, affects Nova1 in the female brain. We hypothesized that
Nova1 expression would decrease in a brain region-specific manner due to age-related
changes in neuronal function and E2 deprivation-related changes in neuroprotection.
Further, we predicted that acute E2 treatment would abrogate the effects of age and
prolonged E2 deprivation on Nova1 expression. To test this hypothesis, female Fisher344
rats were ovariectomized (OVX) at 3 and 18 months of age to study the effects of aging
and administered acute E2 treatment after 1 week. Next, aged animals (18 mo.) were
OVX and administered acute E2 treatment at varying times post-OVX (1-12 weeks
OVX) to assess the effects of prolonged E2 deprivation on Nova1 expression (Fig. 7). We
also quantified the expression of ERβ following Nova1 overexpression, and determined if
there was a direct interaction with ERβ pre-mRNA in hypothalamic-derived neuronal
cells to determine whether Nova1 regulates ERβ alternative splicing. Our data revealed
that Nova1 expression was altered by age and prolonged periods of E2 deprivation in a
brain region-specific manner. Further, we provide evidence that increased Nova1
expression decreased alternative splicing of ERβ and that Nova1 directly interacts with
ERβ pre-mRNA transcripts. Taken together, our results suggest a putative molecular
mechanism regulating the alternative splicing of ERβ.
Briefly, 3 and 18 month old animals underwent OVX and subjected to our E2
deprivation paradigm and then treated with vehicle or E2 (Fig. 7). Circulating E2

	
  

concentration were reported in serum to determine levels of hormone from prior
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studies [188]. A separate group of 18 mo. animals were treated with ERα and ERβselective agonists. To determine the effects of aging and E2 deprivation on Nova1
expression, Nova1 mRNA and protein expression measured in the hypothalamus, dorsal
hippocampus, and ventral hippocampus of these animals. A set of intact animals were
used to compare expression levels of Nova1 in the hypothalamus. An in vitro set of
studies were conducted in cell lines overexpressing Nova1 and/or ERβ2 in order to assess
effects of Nova1 on ERβ alternative splicing.

Results
Nova1 expression changes in the aging brain
No changes were detected in Nova1 mRNA expression in the hypothalamus of
ovarian intact animals at any age (3, 18, 19, 20, 21 mo. old, Fig. 15). By contrast,
comparison of the 3-mo. and 18-mo. OVX animals treated with vehicle or E2 revealed a
significant main effect of treatment on Nova1 mRNA expression in the hypothalamus
(F(1,22)=11.708, p<0.005), dorsal hippocampus (F(1,21)=5.892, p<0.05) and ventral
hippocampus (F(1,21)=14.064, p<0.005) (Fig. 16). In the hypothalamus and dorsal
hippocampus, E2 treatment at 3-mo. significantly increased Nova1 expression when
compared to 18-mo. vehicle- or E2-treated animals (Fig. 16A,B). Conversely, E2
treatment resulted in decreased Nova1 expression in the ventral hippocampus at 3-mo.
when compared to vehicle-treated animals at the same age (Fig. 16C). Nova1 expression
remained significantly low in the ventral hippocampus at 18-mo when compared to 3-mo

	
  

vehicle-treated animals. These data are consistent with previously observed age-related
decreases in Nova1 expression with age.
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Figure 15. Expression of Nova1 mRNA in intact (non-OVX) animals at 3, 18, 19, 20,
& 21 months old. Nova1 mRNA expression was measured in (A) 3 & 18-mo. old
animals and (B) 18, 19, 20, & 21-mo. old (N=6/age). No statistically significant
differences were observed. Data are expressed as mean ± SEM.
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Figure 16. Comparison of Nova1 mRNA expression in the young and aged female
rat brain. Nova1 expression was measured in the (A) hypothalamus, (B) dorsal
hippocampus, and (C) ventral hippocampus at 1 week post-OVX in 3 and 18-mo. old
female rats (N = 6/age/treatment group). Animals were OVX and 1 week later treated
with either vehicle (safflower oil) or 2.5 µg E2 (dissolved in safflower oil). Asterisk ‘*’
indicates a statistically significant difference (p< 0.05) compared to 1 week vehicle and
hashtag ‘#’ indicates a statistically significant difference (p< 0.05) between groups by
Tukey’s Honestly-Significant-Difference Test following two-way ANOVA. Data are
expressed as mean ± SEM.

	
  

Expression of Nova1 is altered by prolonged E2 deprivation in a brain-region specific
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manner in aged female rats
To elucidate the effects of diminished E2 levels on Nova1 expression in the aged
female brain, 18-mo. old animals were OVX then deprived of E2 for increasingly longer
periods of time before acute treatment with vehicle or 2.5 ug/kg E2 once/day for 3
consecutive days (Figure 7). A significant interaction between length of deprivation
(vehicle-treated) and E2 treatment was observed via two-way ANOVA on Nova1 mRNA
expression in the hypothalamus (F(3,41)=52.407, p<0.001) (Fig. 17A), demonstrating the
the expression of Nova1 depends on length of E2 deprivation. There was also a
significant main effect of E2 deprivation time on Nova1 expression in the ventral
hippocampus (F(3,42)=4.496, p<0.01), but not the dorsal hippocampus (Fig. 17C).
Acute E2-treatment in the hypothalamus significantly increased Nova1 expression
8-fold in at 4 weeks post-OVX and 13-fold at 8 weeks post-OVX when compared to
animals treated with vehicle 1 week post-OVX (Fig. 17A). Deprivation of E2 also
significantly increased Nova1 expression in this brain region at 8 weeks. In the dorsal
hippocampus, E2 deprivation significantly decreased Nova1 expression at 4 and 8 weeks
post-OVX and acute treatment with E2 at these time points abrogated these effects (Fig.
17B). In the ventral hippocampus, E2 deprivation resulted in a significant increase at 12
weeks post-OVX, but subsequent acute E2 treatment decreased Nova1 expression at this
time point. There were no changes detected in Nova1 mRNA expression in ovarian intact
animals at these age groups (Fig. 15B).
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Figure 17. Expression of Nova1 mRNA in the brain of aged (18-mo. old) female rats
following varying periods of E2 deprivation. Nova1 mRNA expression was measured
in the (A) hypothalamus, (B) dorsal hippocampus, and (C) ventral hippocampus at 1, 4, 8,
and 12 weeks post-OVX (N = 6-10/age/treatment group). Animals were treated with
either vehicle (safflower oil) or 2.5 µg E2 (dissolved in safflower oil). Asterisk ‘*’
indicates a statistically significant difference (p< 0.05) compared to 1 week vehicle and
‘$’ indicates a greater statistically significant difference (p< 0.001) compared to 1 week
vehicle as determined by Tukey’s Honestly-Significant-Difference Test following twoway ANOVA. Data are expressed as mean ± SEM.

	
  

65	
  
Detection of Nova1 protein in these brain regions revealed a significant main

effect of E2 deprivation time in the hypothalamus (F(3,41)=15.125, p<0.001) (Fig. 18A)
and ventral hippocampus (F(3,42)=55.5, p<0.001) (Fig. 18C), but not in the dorsal
hippocampus (Fig. 18B). Nova1 protein expression significantly increased at 4 weeks in
both vehicle- and E2-treated animals in the hypothalamus (Fig. 18A). Nova1 significantly
increased in the ventral hippocampus at 8 weeks post-OVX in both treatment groups, and
remained elevated up to 12 weeks deprivation (Fig. 18C).
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Figure 18. Expression of Nova1 protein in the brain of aged (18-mo. old) female rats
following varying periods of E2 deprivation. Nova1 and β-actin protein levels were
measured by western blot in the (A) hypothalamus, (B) dorsal hippocampus, and (C)
ventral hippocampus at 1, 4, 8, and 12 weeks post-OVX (N = 6-10/age/treatment group).
Following E2 deprivation, animals were treated with either vehicle (safflower oil) or 2.5
µg E2 (dissolved in safflower oil). Asterisk ‘*’ indicates a statistically significant
difference (p< 0.05) between groups as determined by Tukey’s Honestly-SignificantDifference Test following two-way ANOVA. Nova1 protein levels were quantified after
normalization to β-actin from the same sample. Representative blot images combined
from several gels utilized to perform densitometry quantification of western blots.

	
  

E2-induced increases in Nova1 expression may be mediated primarily by ER
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homodimers
The effects mediated by E2 on ERβ Nova1 could be mediated by either ERα or
ERβ, as both are expressed in each of the brain regions tested [70]. To determine which
E2 receptor mediated observed increases in Nova1, acute administration of the ERβspecific agonist diarylproprionitrile (DPN) or the ERα-specific agonist propyl pyrazole
triol (PPT) was given to 18-mo. old female rats 1-week following OVX. Our results
demonstrated that both DPN and PPT significantly increased expression of Nova1 in the
hypothalamus, yet the effects of PPT on Nova1 expression increased 3.5-fold compared
to 2.25-fold in DPN-treated animals (Fig. 19). Administration of E2 had no effect at this
time point as shown previously (Figure 17A).
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Figure 19. ERα- and ERβ-selective agonists increase Nova1 expression. Nova1
mRNA expression was measured in the hypothalamus of aged female rats that were OVX
and 1 week later treated with either vehicle, E2, 1mg/kg DPN, or 0.5 mg/kg PPT
once/day for three consecutive days (N = 6-8/treatment group). Asterisk ‘*’ indicates a
statistically significant difference (p< 0.05) and ‘$’ indicates a greater statistically
significant difference (p< 0.001) compared to 1 week vehicle as determined by Tukey’s
Honestly-Significant-Difference Test. Data are expressed as mean ± SEM.
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Overexpression of Nova1 decreases ERβ splice variant expression through direct binding
of ERβ mRNA
Nova1 regulates exon splicing through differential binding of the pre-mRNA
transcript. Nova1 promotes exon exclusion if it binds upstream of an alternatively spliced
exon, but it can also promote inclusion of exons if it binds downstream of the exon [143,
145]. The naturally occurring rat ERβ2 splice variant contains an insert in its ligandbinding domain (LBD), which in turn affects its affinity for ligand. This insert is located
between exons 5 and 6 in the ERβ pre-mRNA transcript. The upstream exon 5 has a
cluster of Nova1 binding sites located within its nucleotide sequence (Fig. 6). Similar to
Nova1, we have previously demonstrated that ERβ2 alternative splicing increases in a
brain-region specific manner following E2 deprivation and treatment in the aged rat brain
[96]. Therefore, in order to determine if Nova1 expression affects ERβ2 expression,
Nova1 was transfected in a dose-dependent manner (0.01µg - 2µg plasmid DNA) in vitro
in the IVB rat hypothalamic cell line that endogenously expresses ERβ. The results
demonstrated that overexpression of Nova1 increased total ERβ expression in a dosedependent manner and was statistically significant compared to empty vector at a plasmid
concentration of 0.2 µg/well (Fig. 20A). However, overexpression of Nova1 at all
concentrations resulted in a significant decrease in ERβ2 expression when compared to
pcDNA empty vector (Fig. 20B).
To assess the effects of E2 on ERβ alternative splicing in the presence of Nova1,
IVB cells were transfected with 0.25 µg Nova1, then treated with 100 nM E2 or vehicle
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Figure 20. ERβ alternative splicing decreases with Nova1 overexpression. (A) Total
ERβ and (B) ERβ2 mRNA expression was measured in hypothalamic-derived IVB cells
transfected with Nova1 eGFP plasmid in a dose-dependent (0.01-2ug DNA) (N=34/amount transfected). pcDNA was used as empty vector. Asterisk ‘*’ indicates a
statistically significant difference (p< 0.05) and the ‘$’ indicates a greater statistically
significant difference (p< 0.001) compared to empty vector using t-test.

	
  

(alcohol). There was a significant main effect of treatment on ERβ2 expression in IVB
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cells (F(1,8)=8.624, p<0.05) (Fig. 21B). E2 treatment resulted in a significant decrease in
ERβ2 expression pcDNA overexpressing cells when compared to vehicle-treated cells.
Both vehicle- and E2-treated Nova1 cells had significantly low expression of ERβ2 when
compared to vehicle-treated pcDNA cells. E2 treatment decreased total ERβ expression
in Nova1 transfected IVB cells to levels that were no longer significant when compared
to Nova1 vehicle-treated IVB cells (Figure 21A).
Because Nova1 overexpression had an effect on ERβ splice variant expression,
we hypothesized that Nova1 directly interacts with ERβ mRNA. Nova1- and ERβ-null
HEK cells were co-transfected with Nova1 and ERβ2 for RNA immunoprecipitation
(RIP) analysis. Nova1 was also co-transfected with pcDNA as a negative control. ERβ2
mRNA was enriched in the Nova1-bound RIP between 40-50 fold when compared to
rabbit IgG control (Fig. 22), demonstrating a direct interaction between Nova1 and ERβ
mRNA transcript.
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Figure 21. ERβ alternative splicing decreases with E2 treatment in the presence of
Nova1. (A) Total ERβ and (B) ERβ2 mRNA expression was measured in hypothalamicderived IVB cells transfected with 0.25µg Nova1 eGFP (N = 3). pcDNA was used as
empty vector. Asterisk ‘*’ indicates a statistically significant difference (p< 0.05)
compared to vehicle-treated pcDNA expressing cells as determined by two-way ANOVA
(ERβ2) and t-test (total ERβ).
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Figure 22. Nova1 directly interacts with ERβ mRNA. ERβ mRNA expression was
measured via qRT-PCR following RNA immunoprecipitation with anti-Nova1 antibody
or rabbit IgG in HEK overexpressing Nova1 and ERβ2 (N=3/RIP). Asterisk ‘*’ indicates
statistically significant difference compared to IgG isotype control (p<0.05) by t-test.
Data are expressed as mean fold-enrichment ± SEM.
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Discussion
The Nova1 splicing factor is an important RBP responsible for regulating the

alternative splicing of many different transcripts in the complex environment of the brain.
Our studies present novel findings that age and E2 deprivation affect Nova1 expression in
a brain-region specific manner, supporting the idea that changes in Nova1 have important
consequences for alternative gene splicing postmenopause. Specifically, these
experiments show detailed analyses of the effects of aging on Nova1 expression in the
hypothalamus, dorsal hippocampus, and ventral hippocampus as compared between
young and aged female rats. Further, analysis of Nova1 expression was also conducted in
aged animals that underwent our surgically-induced menopausal model designed to
mimic HT occurring at increasingly longer time points following menopause. The brain
regions tested all express Nova1, as previously observed by immunohistochemistry with
a Nova1 specific antibody, and also express important Nova1-regulated proteins [128,
138, 142, 189]. E2 signaling is physiologically important in these regions, and the actions
of E2 may work in conjunction with Nova1 in neurogenesis and synaptic plasticity [142,
147, 155, 170, 171, 190, 191]. The E2 deprivation-related changes on Nova1 might
further compound the effects of aging in the female brain as previously demonstrated in
the aged male brain [149]. Importantly, we also demonstrate that Nova1 can directly
interact with ERβ mRNA transcripts, providing a mechanism by which alternative
splicing of ERβ is regulated by Nova1. Further evidence of this mechanism is reported
through our Nova1 overexpression studies and their impact on ERβ splice variant

	
  

expression. Taken together, these data contribute to our overall understanding of
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Nova1 and alternative splicing in the aging female brain.
In order to address our hypothesis that aging and/or loss of E2 over long periods
of time alters the expression of Nova1, we used a surgically-induced menopause model
and E2 replacement paradigm. We were able to achieve clinically relevant levels of E2
following administration in our female OVX rats that were similarly reported in
postmenopausal women receiving hormone replacement therapy [34, 96, 172, 188].
Nova1 had been shown to decrease with age in the brain, but these studies were only
conducted in the human male cortex. Our results show similar decreases in Nova1
expression with age in all three brain regions studied. Interestingly, the effects of E2 in
young animals differed between brain regions: treatment in the hypothalamus and dorsal
hippocampus significantly increased Nova1 expression compared to 18-mo., whereas
treatment in the ventral hippocampus significantly decreased Nova1 to levels observed at
18-mo. The loss of Nova1 might be a consequence of the aging brain where neurons are
subjected to increases in oxidative stress [192], perturbed energy homeostasis [193],
DNA damage [194], and accumulation of misfolded/aggregated proteins [195]. The 18mo. old animals in our studies equate to an approximate age of 55 human years old [96].
However, the advanced ages in previous Nova1 studies were conducted in men between
82-86 years old. Therefore, these data suggest that Nova1 expression can potentially
decline in the brain at a younger age.
It is also possible that there are some sex-specific differences in Nova1
expression. In the hypothalamus and ventral hippocampus, Nova1 expression increased

	
  

with longer periods of E2 deprivation (8 and 12 weeks, respectively). This was not true
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for the dorsal hippocampus, which we detected significant decreases in Nova1 expression
after 4 and 8 weeks deprivation. Interestingly, treatment with E2 attenuated these
observed changes in the hippocampus, but not in the hypothalamus, where E2 potentiated
the significant increase in Nova1 expression nearly 3-fold. Several deprivation time
points correlated with Nova1 protein expression, however, not all points that were
significantly altered at the mRNA level corresponded with protein expression. These data
suggest Nova1 expression changes in a brain region specific manner with longer periods
of ovarian hormone deprivation, which may further alter splicing events associated with
neurodegeneration and disease [149, 192, 194]. Specifically in the hypothalamus, it
appears that Nova1 transcription becomes increasingly sensitive to E2 treatment up to 8
weeks deprivation, but these effects do not persist with longer deprivation. This could
occur due to ER-specific expression changes in these regions that occur during ovarian
hormone deprivation [96]. Early E2 replacement (1 week) did not alter Nova1 expression
at the mRNA or protein level, which could maintain persistent expression to prevent
further accumulation of alternatively spliced disease variants in specific brain regions like
the dorsal hippocampus.
Changes in the expression of the nuclear receptors responsible for mediating the
effects of E2 may also play a pivotal role in Nova1 expression. Our lab previously
demonstrated that ERβ expression and alternative splicing is altered with age and E2
deprivation in a brain-region specific manner while others have shown similar effects on
ERα expression with age and neurodegeneration [96, 176, 177, 196-198]. Treatment with

	
  

the ERα-selective agonist PPT and ERβ-selective agonist resulted in a significant
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increase in Nova1 expression, whereas E2 had no effect. Increases in Nova1 may be
mediated by ERα and ERβ independently of each other through homodimerization of the
receptors acting within the Nova1 promoter, whereas heterodimerization may have
inhibitory effects on Nova1 transcription [46]. There are both half estrogen response
elements (EREs) and AP-1 sites predicted within the Nova1 promoter region via
ALGGEN PROMO online prediction software (Table 1). ERs act at these two distinct
sites in different manners, more specifically at AP-1 sites where ERα enhances gene
transcription and ERβ inhibits transcription [52, 199]. Therefore, activation of ERα may
upregulate Nova1, while activation of ERβ may inhibit expression of a factor or miRNA
that downregulates Nova1 expression, such as miR-181b-5p [148]. If heterodimerized,
ERα has been shown to be the dominant partner in ERα/ERβ interactions, whereby ERβ
is no longer able to inhibit Nova1 downregulation [200]. Future studies would need to be
performed to determine the exact mechanism by which ERs regulate Nova1.
ERβ pre-mRNA nucleotide sequence contains many RBP sites that may regulate
its alternative splicing. Among these RBP sites are several Nova1 consensus sites
clustered upstream of the ERβ2 insert. While high throughput studies of Nova1 on premRNA transcripts did not detect an interaction between ERβ and Nova1, it may be
possible that it was undetectable due to the use of whole brain that may wash out more
intricate interactions [140]. We observed correlations with Nova1 expression and ERβ
alternative splicing from our previous studies; therefore we decided to determine if
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location from
transcriptional start site
-633
-1187
AP-1
-1656
Table 1. Location of response elements within the Nova1 promoter. Elements were
predicted with ALGGEN PROMO predictor software (http://alggen.lsi.upc.es/) with
search ERE and AP-1 search parameters. 2kbp of Nova1 promoter were analyzed based
on sequence provided by NCBI database (http://www.ncbi.nlm.nih.gov/gene/4857).
Response element
ERE half-site

	
  

Nova1 regulated ERβ alternative splicing. First, we transfected Nova1 in a dose-

79	
  

dependent manner in hypothalamic-derived IVB cells and observed concomitant
significant increases in total ERβ expression. ERβ2 expression significantly decreased
with Nova1 overexpression when compared to pcDNA even at the lowest dose of Nova1
DNA (0.01µg). These data suggest that Nova1 is mediating increased exon exclusion of
the ERβ2 insert, which results in significantly more wild-type ERβ1 expression. These
effects could counteract splicing silencers like hnRNPs that mediate exon inclusion
events that result in transcripts that are targeted for mRNA nonsense-mediated decay,
therefore increasing transcript numbers to be translated. A similar effect was observed on
dopamine D2 receptors, where Nova1 expression counteracted the effects of hnRNP that
increases the expression of an alternatively spliced dopamine receptor [139]. This
increase coincides with decreased expression of the short form of the dopamine receptor
that is mediated through hnRNP interactions. Interestingly, treatment of cells with E2 in
the absence of Nova1 being overexpressed significantly decreased ERβ2 expression to
levels similar to Nova1 overexpression. Furthermore, treatment of Nova1 expressing cells
with E2 further decreased ERβ2 expression when compared to vehicle-treatment with
Nova1 expression, although not significantly. These results show that Nova1 and E2 are
acting on ERβ alternative splicing with the same outcome: decreased ERβ2 expression.
Interestingly, E2 treatment decreased total ERβ expression in Nova1 expressing cells to
levels that were no longer significant when compared to vehicle-treated Nova1 cells. E2
treatment had no effect on Nova1 overexpression. Therefore, E2 could be affecting
overall availability of ERβ mRNA transcripts that acts independently of Nova1

	
  

overexpression due to differences between total ERβ and ERβ2 expressed. E2 has been
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shown to downregulate ERβ expression in a dose-dependent manner [201]. Thus the
ability of Nova1 to regulate ERβ alternative splicing may depend on the availability of
the pre-mRNA.
RIP experiments revealed a direct interaction between Nova1 and ERβ mRNA.
Interactions with the ERβ pre-mRNA within exon 5 may mediate the exon exclusion
event of the ERβ2 insert. These findings are supported by previous studies that show that
Nova1 binding upstream of an alternatively spliced exon results in exclusion of this exon
[145]. There are also Nova1 consensus sequences located within the intron upstream of
exon 5, which may provide another binding site to mediate the exclusion of the ERβ2
insert. Also, we were unable to detect any predicted sequences downstream of the ERβ2
insert, meaning that Nova1 would likely not mediate exon inclusion, which is also
supported by our findings.
Our model, along with the previous studies outlined in this manuscript, raise
important limitations to consider. The studies by Tollervey and colleagues only studied
Nova1 expression in the cortex of human male patients, whereas our studies were
conducted in female rats in the hypothalamus, dorsal hippocampus, and ventral
hippocampus. Therefore, more studies should be conducted to truly asses the
expressional differences between species, brain regions, and possible sex differences.
While these studies would be largely descriptive, it provides a gap in the literature to
assess the mechanism of alternative splicing of ERβ in a more clinically relevant manner.
These findings would also implicate possible global alternative splicing events that can

	
  

occur with age and loss of circulating E2. I was unable to detect a selected set Nova1-
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regulated genes in our studies (data not shown), however, a large scale detection in
Nova1-regulated alternative splicing would provide insight into this possibility.
Another important aspect to consider is the presence of the Nova1 related RBP
Nova2. Nova2 is generally opposite in expressional patterns in the brain when compared
to Nova1, however these RBPs can overlap in expression in the hypothalamus [202].
More importantly, these two related proteins have highly related KH domains that both
recognize YCAY consensus pre-mRNA sequences [203]. Therefore, we cannot rule out
the possibility that Nova2 may act on ERβ in the same manner as Nova1. This may also
explain some of the differences observed in ERβ alternative splicing between the
hypothalamus and hippocampus as demonstrated in chapter III.
Overall, the results of the present study provide insight into the effects of aging
and prolonged ovarian hormone deprivation on Nova1. We also provide a novel
mechanism by which ERβ is alternatively spliced, and how observed changes in Nova1
expression may alter expression of not only ERβ splice variants but could also alter a
variety of Nova1-regulated proteins in the brain. Consequences of these changes in
expression may further explain the effects of reproductive senescence on cognitive
function and memory, and Nova1 may be a novel therapy target in maintaining efficacy
in hormone replacement therapies. Further investigation into ERβ:Nova1 interactions
could reveal the exact sites on the ERβ pre-mRNA that Nova1 binds and mediates
exclusion of the ERβ2 insert. Nova1 may be a potential therapeutic target for determining
the effectiveness of E2-mediated HT.

	
  

CHAPTER V
AGING AND LOSS OF CIRCULATING 17Β-ESTRADIOL ALTERS THE
EXPRESSION OF SPLICING FACTORS IN THE FEMALE RAT BRAIN
Introduction
The complex regulatory system of post-transcriptional alternative splicing has
many components. Apart from Nova1, there are a plethora of RNA-binding proteins
(RBPs) that are expressed in the central nervous system, some uniquely expressed in
neurons. These include NeuN and ELAV, two well-known RBPs that has also been used
as neuronal markers [204, 205]. These RBPs form a core in ribonucleoprotein (RNP)
complexes that mediate these mechanistic processes of binding consensus sequences on
pre-mRNA transcripts. A recent review has amassed the number of RBPs expressed in
the genome at over 1,500 [206].
While the primary focus of ERβ and the neuron-specific RBP Nova1 have led us
to novel findings outlined in the previous chapters, there are other RBPs that are highly
expressed in these same regions of interest in the brain, notably the hippocampus and
hypothalamus. For instance, Rbfox1 has been shown to control neuronal excitation in the
hippocampus [129]. RBPs not only mediate alternative splicing through direct interaction
with pre-mRNA transcripts, but also mediate spliceosome/ribosome assembly. DEADBox RNA helicase Ddx17 (also known as p72) has been shown to be an important
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component upstream and downstream in ER signaling pathways [207]. Ddx17 has also
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been shown to coordinate splicing events in cooperation with hnRNPH [208]. RBPs are
also able to regulate each other's actions on alternative splicing, such as SR proteins
opposing hnRNP interactions on splice site regulation [209]. Our laboratory has
previously reported that ERβ can interact with hnRNPH1, and this interaction is
enhanced in young (3 month old) female rats when compared with aged (18 month old)
[210]. These studies did not assess the expression of hnRNPH1. Interestingly, Nova1 has
been shown to counteract the effects of hnRNPs on dopamine D2 receptors, altering exon
exclusion events [139]. Members of the CELF/BRUNOL family, Celf4 and Celf5, are
important in brain development and maturation [131]. Celf4/5 are expressed within the
CNS, and Celf4 is thought to be important for both neuronal and myocardial signaling
[130].
The focus of this study was to determine the effects of aging and/or E2
deprivation on splicing factors that are highly expressed in the female brain. We
hypothesized that splicing factor expression is altered in a region-specific manner, like
Nova1, due to age- and E2-related changes that occur in neuronal gene expression. To
test this hypothesis, we OVX Fisher344 rats at 3 and 18 months of age to study the
effects of aging (1 week OVX) and E2 deprivation (1-12 weeks OVX) followed by acute
E2 treatment in these animals (Fig. 7).

	
  

Results

84	
  

HnRNPH1
Comparison of 3-mo. and 18-mo. animals treated with either vehicle or E2
revealed a significant main effect of aging and treatment on hnRNPH1 expression in both
the hypothalamus (F(1,22)=23.263, p<0.001) and dorsal hippocampus (F(1,21)=8.896,
p<0.01) (Fig. 23, A, B). A significant interaction between age and treatment was
observed in the ventral hippocampus (F(1,21)=12.971, p<0.05) (Figure 23C),
demonstrating that the expression of hnRNP-H1 depends on the age that E2 treatment is
administered. The only significant increase in hnRNPH1 expression with age alone (ie.
vehicle-treatment) occurred in the hypothalamus, there was a significant increase in
hnRNPH1 expression in 18-mo. animals when compared to the 3-mo. old animals.
Treatment with E2 potentiated this increase at 18 mo., resulting in highly significant
hnRNPH1 expression. E2 had a significant effect on hnRNPH1 expression in 3-mo. old
animals in both the dorsal hippocampus and ventral hippocampus, but not in 18-mo.
animals.
To elucidate the effects of E2 deprivation on hnRNPH1 expression in the aged
female brain, 18-mo. old animals were OVX then deprived of E2 for increasingly longer
periods of time before treated with vehicle or 2.5 ug/kg E2 once/day for 3 consecutive
days (Fig. 7). A significant interaction between length of deprivation and treatment was
revealed in all three regions: hypothalamus (F(3,41)=3.875, p<0.05); dorsal hippocampus
(F(3,41)=4.955, p<0.05); ventral hippocampus (F(3,40)=3.527, p<0.05) (Fig. 24). In the
hypothalamus, there was a significant increase in hnRNPH1 expression following E2

	
  

treatment at both the 1- and 4-week post-OVX time points (Fig. 24A). E2 treatment
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resulted in a significant increase in hnRNPH1 expression at 8 weeks post-OVX in the
dorsal hippocampus (Fig. 24B). The length of deprivation significantly increased
hnRPH1 expression after 8 weeks when compared to the significant decrease in
expression at 12 weeks post-OVX (Figure 24C). Acute E2 treatment also had varying
effects on hnRNPH1 expression in the ventral hippocampus: E2 significantly increased
expression at 4 weeks post-OVX when compared to the significant decrease in mRNA at
12 weeks.
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Figure 23. Comparison of hnRNPH1 mRNA expression in the young and aged
female rat brain. hnRNPH1 expression was measured in the (A) hypothalamus, (B)
dorsal hippocampus, and (C) ventral hippocampus at 1 week post-OVX in 3 and 18-mo.
old female rats (N = 6/age/treatment group). Animals were OVX and 1 week later treated
with either vehicle (safflower oil) or 2.5 µg E2 (dissolved in safflower oil). Asterisk ‘*’
indicates a statistically significant difference (p< 0.05) compared to 1 week vehicle and
'$’ indicates a greater statistically significant difference (p< 0.001) by as determined
Tukey’s Honestly-Significant-Difference Test following two-way ANOVA. Data are
expressed as mean ± SEM.
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Figure 24. Expression of hnRNPH1 mRNA in the brain of aged (18-mo. old) female
rats following varying periods of E2 deprivation. HnRNPH1 mRNA expression was
measured in the (A) hypothalamus, (B) dorsal hippocampus, and (C) ventral
hippocampus at 1, 4, 8, and 12 weeks post-OVX (N = 6-10/age/treatment group).
Animals were treated with either vehicle (safflower oil) or 2.5 µg E2 (dissolved in
safflower oil). Asterisk ‘*’ indicates a statistically significant difference (p< 0.05)
compared to 1 week vehicle and '#' indicates statistically significant difference between
groups (p<0.05) as determined by Tukey’s Honestly-Significant-Difference Test
following two-way ANOVA. Data are expressed as mean ± SEM.

	
  

Rbfox1
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Comparison of Rbfox1 mRNA expression between 3-mo. and 18-mo. animals
revealed a significant main effect of treatment in the ventral hippocampus
(F(1,21)=4.032, p<0.05) (Fig. 25C) but not in the hypothalamus or dorsal hippocampus
(Fig. 25A,B). However, there were significant effects of E2 treatment in all three brain
regions measured in 3-mo. old animals.
E2 deprivation in aged animals revealed a significant main effect of treatment
in the hypothalamus (F(3,37)=5.343, p<0.05) on Rbfox1 mRNA expression (Fig. 26A).
Also observed were significant main effects of length of E2 deprivation on Rbfox1
mRNA expression in the dorsal hippocampus (F(3,41)=7.007, p<0.01) and ventral
hippocampus (F(3,40)=6.120, p<0.01) (Fig. 26B,C). Acute E2 treatment significantly
increased expression of Rbfox1 1-week post-OVX in the hypothalamus and at 4 weeks in
the ventral hippocampus. Rbfox1 expression was significantly increased in the dorsal
hippocampus after 8 weeks deprivation in both vehicle- and E2-treated animals. This
increase was no longer observed in the ventral hippocampus at 12 weeks E2 deprivation
(post-OVX).
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Figure 25. Comparison of Rbfox1 mRNA expression in the young and aged female
rat brain. Rbfox1 expression was measured in the (A) hypothalamus, (B) dorsal
hippocampus, and (C) ventral hippocampus at 1 week post-OVX in 3 and 18-mo. old
female rats (N = 6/age/treatment group). Animals were OVX and 1 week later treated
with either vehicle (safflower oil) or 2.5 µg E2 (dissolved in safflower oil). Asterisk ‘*’
indicates a statistically significant difference (p< 0.05) compared to 1 week as determined
by Tukey’s Honestly-Significant-Difference Test following two-way ANOVA in the
ventral hippocampus or by t-test in the hypothalamus and dorsal hippocampus. Data are
expressed as mean ± SEM.
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Figure 26. Expression of Rbfox1 mRNA in the brain of aged (18-mo. old) female rats
following varying periods of E2 deprivation. Rbfox1 mRNA expression was measured
in the (A) hypothalamus, (B) dorsal hippocampus, and (C) ventral hippocampus at 1, 4, 8,
and 12 weeks post-OVX (N = 6-10/age/treatment group). Animals were treated with
either vehicle (safflower oil) or 2.5 µg E2 (dissolved in safflower oil). Asterisk ‘*’
indicates a statistically significant difference (p< 0.05) compared to 1 week vehicle as
determined by Tukey’s Honestly-Significant-Difference Test following two-way
ANOVA. Data are expressed as mean ± SEM.
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Analysis of Ddx17 expression comparing 3-mo. and 18-mo. old animals reported
significant main effects of aging in the hypothalamus (F(1,21)=56.752, p<0.001) and
dorsal hippocampus (F(1,20)=10.05, p<0.01) (Fig. 27A,B). A significant main effect of
treatment on Ddx17 expression was also observed in the dorsal hippocampus
(F(1,20)=4.933, p<0.05). There were no significant effects observed in the ventral
hippocampus (Fig. 27C). Overall expression of Ddx17 was significantly elevated in the
18-mo hypothalamus, and the same was also true in the dorsal hippocampus with E2
treatment-only.
The loss of E2 had a significant main effect in both the dorsal hippocampus
(F(3,40)=62.896, p<0.001) and ventral hippocampus (F(3,39)=8.915, p<0.01) on Ddx17
expression (Fig. 28B,C). There were no significant effects observed in the hypothalamus
with increasing deprivation time or E2 treatment (Fig. 28A). E2 deprivation significantly
increased Ddx17 levels after 4 weeks deprivation, but the effect was lost with longer
periods of deprivation. E2 treatment significantly increased Ddx17 expression at 4 weeks
deprivation in the dorsal hippocampus, with overall expression remaining significantly
increased in both treatment groups at 8 weeks deprivation. These effects are lost at the 12
week time point.
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Figure 27. Comparison of Ddx17 mRNA expression in the young and aged female
rat brain. Ddx17 expression was measured in the (A) hypothalamus, (B) dorsal
hippocampus, and (C) ventral hippocampus at 1 week post-OVX in 3 and 18-mo. old
female rats (N = 6/age/treatment group). Animals were OVX and 1 week later treated
with either vehicle (safflower oil) or 2.5 µg E2 (dissolved in safflower oil). Asterisk ‘*’
indicates a statistically significant difference (p< 0.05) compared to 1 week as determined
by Tukey’s Honestly-Significant-Difference Test following two-way ANOVA. Data are
expressed as mean ± SEM.
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Figure 28. Expression of Ddx17 mRNA in the brain of aged (18-mo. old) female rats
following varying periods of E2 deprivation. Ddx17 mRNA expression was measured
in the (A) hypothalamus, (B) dorsal hippocampus, and (C) ventral hippocampus at 1, 4, 8,
and 12 weeks post-OVX (N = 6-10/age/treatment group). Animals were treated with
either vehicle (safflower oil) or 2.5 µg E2 (dissolved in safflower oil). Asterisk ‘*’
indicates a statistically significant difference (p< 0.05) compared to 1 week vehicle as
determined by Tukey’s Honestly-Significant-Difference Test following two-way
ANOVA. Data are expressed as mean ± SEM.

	
  

Celf4 and Celf5
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Comparisons of the CELF/BRUNOL factors Celf4 and Celf5 between 3-mo. and
18-mo. old animals revealed significant main effects of aging on expression of Celf4
(F(1,21)=17.43, p<0.001) and Celf5 (F(1,21)=16.266, p<0.001) in the hypothalamus
(Figures 29A & 30A). There was also a significant interaction between aging and
treatment on Celf4 expression in the ventral hippocampus (F(1,20)=6.534, p<0.05)
(Figure 29C). Expression of Celf4 and Celf5 were significantly increased in the
hypothalamus with E2 treatment in the 18-mo. females, although vehicle treatment also
significantly increased Celf5 expression at this age (Figs 29A & 30A). In the dorsal
hippocampus, there was a significant increase in Celf5 from E2 treatment in 3-mo. old
animals (Figure 30B). In the ventral hippocampus, there was a significant increase in
Celf4 expression following E2 treatment in 3-mo. animals, whereas Celf5 expression
significantly increased in 18-mo. animals (Figures 29C & 30C).
In female rats deprived of ovarian hormones, there was a significant interaction
between timing and treatment on Celf5 expression in the dorsal hippocampus
(F(3,40)=18.589, p<0.001) and ventral hippocampus (F(3,39)=5.048, p<0.01) (Figure
32B,C). A significant interaction also occurred in the ventral hippocampus on Celf4
expression (F(3,39)=6.723, p<0.001) (Figure 31C). A significant main effect of
deprivation was observed in the dorsal hippocampus (F(3,40)=6.499, p<0.001) on Celf4
expression (Figure 31B). While no significant interactions or effects were observed in the
hypothalamus on either Celf4 or Celf5, there was a significant increase in Celf5
expression at 4 weeks deprivation following E2 treatment (Figure 32A). This same E2
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Figure 29. Comparison of Celf4 mRNA expression in the young and aged female rat
brain. Celf4 expression was measured in the (A) hypothalamus, (B) dorsal hippocampus,
and (C) ventral hippocampus at 1 week post-OVX in 3 and 18-mo. old female rats (N =
6/age/treatment group). Animals were OVX and 1 week later treated with either vehicle
(safflower oil) or 2.5 µg E2 (dissolved in safflower oil). Asterisk ‘*’ indicates a
statistically significant difference (p< 0.05) compared to 1 week vehicle as determined
Tukey’s Honestly-Significant-Difference Test following two-way ANOVA. Data are
expressed as mean ± SEM.
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Figure 30. Comparison of Celf5 mRNA expression in the young and aged female rat
brain. Celf5 expression was measured in the (A) hypothalamus, (B) dorsal hippocampus,
and (C) ventral hippocampus at 1 week post-OVX in 3 and 18-mo. old female rats (N =
6/age/treatment group). Animals were OVX and 1 week later treated with either vehicle
(safflower oil) or 2.5 µg E2 (dissolved in safflower oil). Asterisk ‘*’ indicates a
statistically significant difference (p< 0.05) compared to 1 week vehicle as determined
Tukey’s Honestly-Significant-Difference Test following two-way ANOVA. Data are
expressed as mean ± SEM.
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Figure 31. Expression of Celf4 mRNA in the brain of aged (18-mo. old) female rats
following varying periods of E2 deprivation. Celf4 mRNA expression was measured in
the (A) hypothalamus, (B) dorsal hippocampus, and (C) ventral hippocampus at 1, 4, 8,
and 12 weeks post-OVX (N = 6-10/age/treatment group). Animals were treated with
either vehicle (safflower oil) or 2.5 µg E2 (dissolved in safflower oil). Asterisk ‘*’
indicates a statistically significant difference (p< 0.05) compared to 1 week vehicle and
'#' indicates statistically significant difference between groups (p<0.05) as determined by
Tukey’s Honestly-Significant-Difference Test following two-way ANOVA. Data are
expressed as mean ± SEM.
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Figure 32. Expression of Celf5 mRNA in the brain of aged (18-mo. old) female rats
following varying periods of E2 deprivation. Celf5 mRNA expression was measured in
the (A) hypothalamus, (B) dorsal hippocampus, and (C) ventral hippocampus at 1, 4, 8,
and 12 weeks post-OVX (N = 6-10/age/treatment group). Animals were treated with
either vehicle (safflower oil) or 2.5 µg E2 (dissolved in safflower oil). Asterisk ‘*’
indicates a statistically significant difference (p< 0.05) compared to 1 week vehicle and
'#' indicates statistically significant difference between groups (p<0.05) as determined by
Tukey’s Honestly-Significant-Difference Test following two-way ANOVA. Data are
expressed as mean ± SEM.

	
  

effect at 4 weeks was also observed in the dorsal hippocampus; however, there was a
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significant increase with deprivation after 8 weeks, where E2 treatment at this time point
attenuated this increase (Figure 32B). Celf4 and Celf5 expression in the ventral
hippocampus had no significant differences when compared with 1 week vehicle-treated
animals, but there significant differences in later deprivation time points (Figure 31C &
32C).

Summary
The results from these studies demonstrate that aging and loss of E2 in the aged
female brain affect RBPs that are integral for coordinating a variety of alternative
splicing events. These data provide further evidence that these physiological changes
affect a broader set of RBPs in a region-specific manner beside the neuron-specific
Nova1 splicing factor studied in chapter IV. Taken together, these data suggest that
alternative splicing events may be altered in tissues where these RBPs are expressed,
contributing to the decline in health that is associated with aging and reproductive
senescence. These data also provide further targets to study the effects on ERβ alternative
splicing that may also occur in brain and other organ systems.
HnRNPH1 is a critical RBP that acts on splice site silencers (SSS), whether
intronic or exonic [187, 209]. This RBP works in coordination with Ddx17 to regulate
splicing programs during cell differentiation [208]. These two factors also orchestrate
transcription, and have both been implicated in E2 signaling through protein:protein
interactions [207, 210]. The effects of aging and E2 deprivation on hnRNPH1 expression

	
  

demonstrated in these studies may in turn affect the interaction of this RBP with ERβ
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as observed previously by our laboratory. Our data demonstrate that this RBP is altered
primarily by E2, and loss of E2 over time appears to no longer maintain expression of
hnRNPH1 in these brain regions. If alternative splicing increases with age, the increase in
hnRNPH1 may be due to a compensatory mechanism to limit the number of alternative
splicing events that can occur as our data suggest in the hypothalamus. E2 potentiated
this increase even further, which may imply further benefits of E2 treatment in aged
individuals. The brain region specific changes were apparent when comparing the effects
of age on hnRNPH1 in the hippocampus, where it significantly increased in 3 mo. old
animals but not 18 mo. old. E2 has been shown to upregulate cell proliferation in the
hippocampus, however this effect is lost with longer periods of hormone deprivation [79].
While there is a significant effect of E2 in later stages of our hormone deprivation in the
hippocampus, the effects of hnRNHP1 on these processes may rely on other factors
present, like Ddx17. As stated previously, hnRNPH1 is also important for cell
differentiation, and the pool of neural progenitor cells decreases significantly with age in
the hippocampus [211]. This may be why E2 treatment significantly increased expression
of hnRNPH1 in both the dorsal and ventral hippocampus in 3 mo. old animals as an
important mediator of cell proliferation where these progenitor pools are still high.
However, loss of hnRNPH1, like in the ventral hippocampus with E2 deprivation, and its
possible recruitment to the transcriptional complex by ERβ may alter expression of splice
variants that rely on recognition of splice site silencing through hnRNPH1 [208]. These
interactions may be further altered by the expressional differences in ERβ1 and ERβ2

	
  

previously outlined in chapter III that occur in the brain during aging and loss of E2.
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Further studies on ERβ interaction with hnRNPH1 may reveal more on the dependency
of these two factors for expression of ER-regulated gene expression and/or alternative
splicing events.
Ddx17 is an important regulator of ER signaling, mainly through control of the
expression of key regulators of ER activity [207]. These include kinases important for
phosphorylation of ERs like cyclin-dependent kinase 2 (CDK2) and mitogen-activated
protein kinase (MAPK) 1. Ddx17 also acts downstream as a required factor for
transcriptional and splicing regulation of ER-regulated genes like nuclear receptor corepressor 2 (NCOR2). Like hnRNPH1, Ddx17 expression drastically increases with age
in the hypothalamus, therefore it is possible that the expression of this RBP is regulated
under similar mechanisms as hnRNPH1. There are also similar expression patterns
between these two RBPs in the hippocampus, which may echo the previous statements
about cell differentiation with hnRNPH1 in this brain region. However, the
responsiveness to E2 is lost in the advanced deprivation time periods in all brain regions.
These effects may impact ER regulation of transcription and splicing of E2 target genes,
such as glycogen synthase kinase-3 (GSK3)β. Further studies on Ddx17 expression and
the impact on steroid hormone signaling warrants further investigation due to the master
regulator status of Ddx17.
Interestingly, Rbfox1 expression was not altered as much by age in the ventral
hippocampus, but drastically increased in the dorsal hippocampus and hypothalamus.
Brain region specificity on Rbfox1 expression was also observed in the E2 deprivation

	
  

paradigm, where deprivation had affects in the hippocampus, but not the
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hypothalamus. Rbfox1's role in development and on synaptic transmission in the brain
make this an RBP to which altered expression could have implications on behavior and
memory [129]. Rbfox1 can also regulate hnRNPH1 and Ddx17 expression, therefore
impacting expression of a whole set of alternatively spliced genes regulated by these
RBPs [212]. Rbfox1, hnRNPH1, and Ddx17 expression change in a relatively consistent
manner with E2 deprivation, however there appear to be greater differences when
comparing these RBPs in our aging model. These differences may be dependent on
another set of factors that interact with Rbfox1 and/or these other RBPs to regulate their
expression that could mirror their importance to brain development.
The CELF/BRUNOL factors had the least amount of significant differences
between aging and E2 deprivation in the brain regions studied when compared with the
other RBPs covered in our studies. These data reveal that both Celf4 and Celf5 are altered
greatly in the hippocampus when compared with the hypothalamus with regards to
hormone deprivation, however, the largest differences with aging occurred in the
hypothalamus when compared with the hippocampus. Celf4 is an important regulator of
synaptic plasticity in a similar manner as Rbfox1, therefore loss of this factor could
contribute greatly to alternative splicing events that affect brain physiology and behavior
[130, 131]. While there is little known about Celf5 other than its neuron-specific
expression, it could also mediate important alternative splicing events due to it
homologous nature to Celf4. It is interesting that its expression did not follow the same
expressional profile pattern as Celf4 in the dorsal hippocampus with age, but it appears

	
  

that the other regions examined had similar differences between these two highly
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related factors.
These factors studied in this chapter, may have far reaching consequences due to
altered expression patterns, all which provide possible mechanisms for the negative
effects associated with aging and diminished levels of E2 in the aged female brain.
However, these studies are limited to their descriptive nature, and follow up studies on
the implications of these RBPs being altered by age and/or E2 deprivation may provide
more insight on alternative splicing outcomes in the brain.

	
  

CHAPTER VI
FINAL DISCUSSION

Summary of Key Findings
The outcomes from the WHI studies brought to light an important observation
that there is a critical window in which HT is beneficial. After this period of time, the
negative effects of HT present adverse health outcomes in postmenopausal women. If the
efficacy of E2 is no longer valid, then it is becomes important to understand why. While
there are many different avenues to take, understanding the receptors by which this
ovarian hormone mediates its actions should be of utmost importance. There is evidence
that alternative splicing events increase in the brain with age. The impact of ERβ splice
variants are becoming more apparent through both human and rat studies. Therefore, the
goals of this project were to examine the mechanism by which alternative splicing of ERβ
occurs in the aged female brain. In chapter III, the data show that both aging and loss of
E2 contribute to altered expression of ERβ splice variants. Chapter IV revealed that the
expression of Nova1, an important neuronal RBP for regulating a multitude of alternative
splicing events, is also affected by loss of E2 in the aged female brain. The studies done
in chapter V continue upon these changes that can occur in alternative splicing, as a
number of other RBPs are affected by age- and E2-related changes. However, the novel
findings that Nova1 may regulate ERβ alternative splicing through interactions with the
104	
  

	
  

ERβ mRNA shown in chapter IV may provide the most integral target to study in the
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regulation of ERβ alternative splicing in the aging female brain. Taken together, the data
presented in this dissertation provide novel mechanisms for age-related changes in ERβ
alternative splicing, and demonstrate how loss of E2 can potentially affect global
alternative splicing events that may potentiate these effects in postmenopausal women
who seek HT.

Menopause and ERβ Alternative Splicing
The findings presented in chapter III make significant contributions toward
understanding the how age-related changes can affect the alternative splicing of ERβ.
Also presented in this chapter are the significant findings of how E2 deprivation can
affect the alternative splicing of ERβ. These two contributing factors occur in a brain
region specific manner. Therefore, the rate at which the brain is altered due to increased
age and loss of E2 may be significantly different between brain regions, and that the
predominant receptor expressed in these regions is the dominant negative ERβ2 splice
variant. ERβ2 is considered a dominant negative splice variant due to its decreased
affinity for ligand and opposing effects on ER-mediated signaling [102, 201, 213].
Ultimately, the expression of this receptor may contribute to the reduced efficacy through
reduced ligand-binding affinity associated with HT, and the differential expression of this
splice variant receptor between brain regions may shift the critical window of HT
between regions.

	
  

These findings presented in the context of a window of time are very
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appropriate. The window is 'open' widest during a woman's early pre-pubertal life up to
pre-perimenopause. E2 signaling is maintaining homeostatic environments in both the
brain and throughout the body as ovarian hormone productions remains consistent. As E2
production begins to slow down and becomes acyclic, the critical window begins to
close. At this point in time, ER alternative splicing events may begin, shifting dominance
from the wild-type ERβ to the dominant negative ERβ2. These mechanisms must also
take into the account the age of the individual at which this occurs, as aging contributes
to increases in alternative splicing [149]. E2-regulated gene expression of RBPs most
likely sets these early alternative splicing changes in motion. There can also be subtle
fine-tunings of these changes that can also begin altering alternative gene transcripts
through mRNA stability [214].
E2 is also known to regulate non-genomic effects within cells through the GPER,
mediating secondary messengers that affect cell metabolism [63, 69]. Increases in
oxidative stress due to aging can affect these processes, and altered expression of ERs,
whether NR or GPCR, can influence these actions. There have also been several GPER
alternative splice variants that differ in the 5’ untranslated region (UTR), although little
has been studied about these variants. However, changes to the 5’ UTR can affect the
open reading frame of the mRNA to be translated, thereby regulating the expression of
the protein [215]. Expressional differences in GPER could have negative implications on
E2 gene regulation, especially in activating kinases important for E2 signaling like Erk2
[61].

	
  

When menopause occurs, the diminished levels of E2 circulating in the body
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may accelerate the mechanisms that increase alternative splicing, which we know can be
compounded by aging. Leading in to early postmenopause, the window is still open but is
beginning to close at a steady rate. Studies on alternative splicing and aging have
provided a basis to what could be occurring during this natural process [149, 216]. Our
observations of not only altered expression of RBPs due to age but also due to E2 brings
to light the reality of sex-specific aging. It is entirely possible that these changes could be
a compensatory mechanism to acclimate to the changing hormonal environment, which
may be why there is a hypersensitivity to E2 treatment on ERβ and certain RBP mRNA
expression within the different brain regions. However, these changes may come at a cost
to brain processes, which can begin impacting cognitive function, where memory deficits
and mood disorders begin to manifest [15, 16]. The persistent low levels of circulating E2
and age-related effects on alternative splicing could in turn be becoming the molecular
steady state within neurons, and these cells begin working with what they have, although
a much better prognosis would be for continuous E2 circulating throughout the body.
Altered expression of ERβ splice variant expression was observed with aging in the
hypothalamus in aged rats, to which we equate based on previous estrous cycle and
survival studies to a 50-56 year old woman who is in the menopausal transition to early
postmenopause [181]. While there was not a significant change in ERβ expression in the
hippocampus, there was no longer an effect of E2 on its expression. This may have to do
with changes in RBPs that regulate the alternative splicing of ERβ that are now altered in
this brain region, as will be discussed later.

	
  

Eventually, the window will 'close', and the benefits of HT will be lost.
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However, the concept of a critical window by which HT is beneficial must be
reexamined. These data present the idea that there isn't just one window: there are
multiple windows of time in which HT is beneficial. These windows are open in
conjunction with each brain region, and one window closing does not mean all of them
are closing. For example, the efficacy of E2 on hypothalamic processes may be longer
than the efficacy of E2 on hippocampal process; therefore, the critical window for HT is
open much longer in the hypothalamus than in the hippocampus.
In the context of the hippocampus, ERβ expression changes rapidly during the
early deprivation stages. This brain region is the epicenter of memory, and many studies
in postmenopausal women have shown a decline in memory [20, 162, 174]. Our findings
in chapter III show that ERβ2 splice variant becomes the dominant form of the receptor
in this region of the brain, therefore HT may no longer benefit this brain region. These
data further corroborate similar findings in middle-aged rats who underwent prolonged
E2 deprivation [79]. Increased ERβ2 expression may contribute to the cognitive deficits
in this brain region, as E2 has been shown to increase hippocampal neurogenesis and
improve memory through spine density and synaptic plasticity [83, 85, 217]. In both the
dorsal and ventral hippocampus after 4 weeks deprivation there was a significant
decrease in total ERβ expression. Following E2 treatment, total ERβ expression
significantly increased, while the ERβ2 fraction maintained a consistent expression level
compared to untreated animals at this time point. The effect of E2 treatment on ERβ
expression in the hippocampus is gone after 8 weeks, and never recovers. This 4 week

	
  

time points signals a critical period in the hippocampus where there may still be
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responsiveness to E2 and this time point is still within that critical window of time for a
postmenopausal women undergoing HT (19-mo. old rat = human 53-59 years of age) as
determined in chapter III. After 8 weeks of ovarian hormone deprivation, the efficacy of
E2 could be lost, as has been observed in postmenopausal women within the latter of this
age range (20-mo. rat = 56-62.5 year old human). Observations in animals who
underwent prolonged E2 deprivation displayed decreased hippocampal neurogenesis as
ERβ2 expression increased [79]. These studies also showed that animals with increased
ERβ2 expression exhibited more depressive-like behaviors, providing another link to the
effects of ERβ alternative splicing in the hypothalamus.
E2 deprivation did not have the same effect in the hypothalamus, where there is
still a complimentary amount of both ERβ isoforms with prolonged deprivation (up to 12
weeks). These region specific differences must rely on a multitude of conditions that
could be changed in the hippocampus but not in the hypothalamus, such as the presence
of brain-region specific RBPs. However, this region is linked to mood disorders and
homeostasis, so these behavioral changes could be related in part to the age-related
changes in ERβ expression and not to deprivation. Therefore, HT may still provide
benefits to the hypothalamus in later stages of postmenopause, but due to the expressional
profile of ERβ2 in the hippocampus, the hypothalamic-associated benefits may have
negative consequences in the hippocampus.
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Expression of RNAPII and its activity have been studied little in the context of
aging and E2 deprivation. A study done in the 1980's observed that E2 administration
following OVX in female rats significantly increased the activity of RNAPII 12-18 hours
after E2 treatment [218]. I hypothesized that E2 would not only have an immediate effect
on RNAPII, but a long lasting effect due to reproductive senescence. It was also
hypothesized that RNAPII expression may be altered in a brain-region specific manner
due to aging and loss of circulating E2. In our studies conducted in chapter III, we found
that RNAPII expression and activity was indeed altered by aging and E2 deprivation in a
brain region-specific manner.
While there isn't a direct link between E2 and RNAPII expression/activity, E2
may act either directly or indirectly to have the effects observed in the brain. ERβ is a
well-known transcription factor that interacts with a variety of coregulatory elements that
in turn interact with RNAPII to initiate transcription [219]. Through altered expression of
ERβ and its splice variants, the availability of ERβ and/or its transcriptional activity (ERβ
splice variants can also act in a ligand-independent manner) could influence RNAPII at
E2-regulated genes. Therefore, the activity of RNAPII would increase or decrease based
upon the expression of ERβ. However, these E2-regulated genes could be important
proteins that interact directly with RNAPII, resulting in decreased association of RNAPII
with integral transcription factors. These findings could broaden the implications of loss
of E2 on not only ERβ expression and its alternative splicing, but on global gene
expression and global alternative splicing.
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alternative splicing changes in the brain with age and E2 deprivation. While RNAPII
expression and activity may play a large role in this mechanism, RNAPII is known to
also interact with a host of RBPs via its C-terminal region. These interactions rely on the
phosphorylation of this domain, which is interesting in that phosphorylation of RNAPII
C-terminal region also affects the rate of transcription [166]. Hyper-phosphorylation of
RNAPII can slow down transcription, yet phosphorylation is required for this enzyme to
be active. This slowing of RNAPII could allow factors attached to the C-terminal
domain to recognize RBP motifs to mediate splicing events, and in some case, alternative
splicing. E2 can regulate the kinase CDK9 that phosphorylates RNAPII in ERα+ breast
cancer cell lines, although this has not been studied in the context of the brain [220].
Therefore, it is possible that E2 could also be regulating the rate at which RNAPII
transcribes RNA and also alternative splicing events through RBP recruitment.
A novel compound called camptothecin can inhibit TOPI through competitivebinding [178]. Inhibiting the activity of TOPI stalls RNAPII on the DNA, resulting in
slowed transcriptional kinetics. The evidence that transcription and splicing are coupled
processes have been demonstrated with the interaction of RNAPII and RBPs as stated
previously, and have been studied extensively the past decade [165, 168, 169]. Therefore,
stalling RNAPII allows time for RBPs to mediate alternative splicing events whose
probability of occurring is reduced due to the location of cis RBP binding sites or weak
splice sites [166]. Another aspect to this phenomenon is that the size of the intron
between alternatively spliced exons can also influence these events. Shorter intronic
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treatment [167]. The intronic element upstream of the ERβ2 insert is about 900bp, and
contains weak splice sites at the appropriate 5' and 3' sites that can be recognized by
spliceosome components [117]. We observed a significant increase in ERβ2 expression
following TOPI inhibition in the ERβ-expression GT1-7 hypothalamic cell line.
However, E2 treatment in coordination with camptothecin eliminated this effect. In the
context of breast cancer, E2 can overcome RNAPII transcriptional stalling by recruiting
CDK9 to the transcriptional complex [221]. While there is no evidence that stalled
RNAPII is hypophosphorylated, the association of ERs with kinases and other
transcriptional regulatory components may counteract these effects in vitro. Slowing of
transcription in vivo would most likely have detrimental effects on cell survival. Cells
treated with camptothecin for more than 24 hours or with higher doses undergo apoptotic
cell death [222]. However, these observations provide novel findings about the ERβ
mRNA transcripts and how its structure may influence its alternative splicing as well as
global alternative splicing through its subsequent function.

Nova1 expression changes in a brain region-specific manner
Prior to these studies, Nova1 has not been shown to associate or regulate the
alternative splicing of ERβ. While this was the ultimate goal of these studies, there were
several more gaps in the literature that would lead us to these findings. Namely, Nova1
was shown previously to be downregulated by the synthetic GC dexamethasone in vitro
in a hypothalamic cell line [147]. These findings appear to be the only demonstration by

	
  

which steroid hormones were used to study regulation of Nova1 expression. Recent in
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vivo studies demonstrated that Nova1 decreased with age in male cortical samples [149].
It should be noted that these studies did not include female subjects. Scanning the
promoter of Nova1 contains an ERE half site as well as several AP-1 sites upstream of
the transcription start site. These findings along with our previous observations of aging
and ovarian hormone deprivation on ERβ alternative splicing led us to target Nova1 as a
potential RBP that is regulated not only by E2 but also by aging in females. This in turn
may provide more evidence for the role of Nova1 in the alternative splicing of ERβ. The
findings in chapter IV revealed that Nova1 decreased with age in female OVX rats, and
that E2 deprivation and subsequent treatment altered the expression of this RBP. E2 was
unable to increase Nova1 expression in 18 month animals to levels observed at 3 months
in the studied brain region. These brain region-specific Nova1 decreases may occur due
to the synergy of diminished E2 levels and increased cortisol levels that can accumulate
over time [223]. These increases in cortisol result in an increase GC production, and GCs
can act in opposing manners to E2 on gene expression [224].
However, Nova1 expression in the dorsal hippocampus and hypothalamus was
responsive to E2 treatment in the younger animals, where treatment resulted in a
significant upregulation of Nova1. We also observed significant increases in Nova1
expression following treatment with the ERα-selective agonist PPT in 18 month old
animals. ERα expression has been shown to decrease with age in a brain region specific
manner [70, 225]. Therefore these brain region specific changes in Nova1 expression

	
  

with loss of circulating E2 may be due to combinatorial loss of ERα and ERβ
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expression with age in the hypothalamus, but may rely on other factors in the
hippocampus.
The loss of E2 over extended periods of time had an interesting effect on Nova1
expression at both the mRNA and protein level. Nova1 significantly increased with
longer periods of deprivation in the hypothalamus and ventral hippocampus. However,
these increases occurred at different time points in the deprivation paradigm, and Nova1
expression in the hypothalamus becomes nearly undetectable after 12 weeks. This could
be due to mRNA stability, as well as protein stability and turnover within this
environment. Even more surprising was the effect of E2 in the hypothalamus: Nova1
mRNA expression increased nearly 13-fold when compared to 1 week treated animals.
The hypersensitivity to E2 on Nova1 expression may be a consequence of the deprivation
paradigm: an influx of circulating E2 to a deprived system may signal to the cell to
quickly upregulate primed genes. RNAPII can be preloaded at the promoter of E2regulated genes ready to initiate transcription [226]. Ligand-bound ERs activate RNAPII
at these sites to rapidly induce transcription, and a majority of E2-regulated genes were
found to have RNAPII preloaded at many of these promoter sites. There are also rapid
non-genomic effects of GPER that could also prime the cells to rapidly upregulate
expression of Nova1 during the 3 day regiment of E2 treatment. However, the regionspecific differences may be dependent upon the expressional levels of ERs and
transcription factors needed to recruit RNAPII.

	
  

The altered expression of Nova1 due to aging and E2 deprivation can have a
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variety of implications on alternative splicing events. Nova1 is critical in the expression
of several receptors in the brain, including dopamine receptors. Knockdown studies of
Nova1 revealed aberrations in dopamine D2 receptor alternative splicing, resulting in
increased expression of the short form of the receptor [139]. While this form of the
receptor is important for presynaptic functions like neuronal firing and dopamine release,
loss of Nova1 expression decreases expression of the long form of the D2 receptor, which
is important for postsynaptic processes [96, 124]. Mouse models of D2 long receptor
knockouts have deficits in motivated behaviors and learning [124, 227]. These findings
were echoed in studies involving D2 expression in the hippocampus on learning and
working memory [228]. Therefore the altered expression of Nova1 may affect the relative
expression of these two forms of the receptor that may affect downstream process
associated with cognitive function in aged individuals deprived of circulating E2.

Nova1 regulation of ERβ alternative splicing
Up to this point, our findings demonstrated that aging and E2 deprivation alter
ERβ alternative splicing and Nova1 expression. These observations led us to pursue the
possibility that Nova1 may play a regulatory role in the alternative splicing of ERβ,
whether directly or indirectly. Several Nova1 consensus sequences were found when
scanning the ERβ pre-mRNA transcript, although a cluster of sequences were found
directly upstream of the ERβ2 insert within exon 5 (Figure 6). The canonical ERβ2 54bp
insert is located within the intron between exons 5 and 6. This YCAY consensus cluster
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exon exclusion, or loss of the ERβ2 insert. I hypothesized that increased expression of
Nova1 would decrease ERβ2 expression, and that Nova1 could mediate this effect by
directly binding to ERβ pre-mRNA.
Our findings confirm that Nova1 directly binds to ERβ mRNA, and we also
provide evidence that Nova1 overexpression significantly decreases ERβ2 expression.
The model proposed in Figure 33 shows how Nova1 enhances exclusion of the ERβ2
insert through excision of the entire intron containing the 54bp. Nova1 recognizes the
YCAY sequence cluster located within exon 5. This may also be coordinated by Celf4/5
RBPs as discussed later in this chapter. Upon binding, Nova1 enhances the U1 snRNP
binding to the 5' splice site. U2AF locates the branch point to assist the binding of U2 to
this site, forming the initial A/E complex. This branch point must be located downstream
of the 54bp insert, and protein:protein interaction through Nova1 on other spliceosome
components must guide the U2AF to this point. There have not been many studies that
have determined the interactions between Nova1 and the spliceosome machinery,
however there is evidence of Nova1 interactions with the splicing regulator TIAR [135].
This regulator can form a complex with U1 snRNP, therefore facilitating U2 snRNP
binding to the correct branch point.
An equally interesting possibility is that Nova1 could be competing with other
splicing factors that may enhance the inclusion of the ERβ2 insert. HnRNPH1 can bind to
splice site silencers to inhibit the actions of Nova1, as observed with another hnRNP
called hnRNP M on dopamine D2 splicing regulation [139]. It may be that Nova1
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117	
  

equally important splicing factor, such as SRSF2, that may enhance exon inclusion,
which would lead to a significant increase in ERβ2 expression. SRSF2 binds ESEs to
enhance exon inclusion events through recruitment of U2AF to the branch point of the
upstream intron to be excluded. Using ESEFinder 3.0 (http://rulai.cshl.edu/cgibin/tools/ESE3/esefinder.cgi), there is an SRSF2 site located within the intron upstream
of the ERβ2 insert. Binding of U2 to this branch point would most likely result in
excision of the intronic element upstream of the ERβ2 insert, therefore including this
insert in the mature mRNA transcript. SRSF2 may also be working in conjunction with
hnRNPH1 to mediate ERβ2 inclusion as shown in Figure 34. Future studies on other
possible RBP interactions with ERβ pre-mRNA will likely yield the finer details on ERβ
alternative splicing regulation.
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Figure 33. Nova1 promotes exclusion of the 54bp ERβ2 insert. Nova1 binds to YCAY
consensus sequences located in exon 5. Celf4/5 coordinate Nova1 binding. Upon binding,
Nova1 enhances assembly of the U1 snRNP at the splice site located directly downstream
within the intron. The U2 snRNP recognizes the intron branchpoint, binds, and assists in
guiding the U4/U5/U6 trimer to form the core spliceosome B complex. Nova1, U1 and
U4 snRNPs dissociate, and the remaining complex (C complex) becomes catalytically
active to excise the ERβ2 containing intron through successive transesterification
reactions. The final step, after the lariot formation, ligates the coding exons together to
form the ERβ1 transcript.
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The nature of our E2 deprivation model gives us the ability to study the effects of
diminished ovarian hormones on a variety of targets. Due to the fact that we saw changes
in the RBP Nova1, we sought to investigate how aging and loss of E2 might affect other
integral RBPs. 15 different RBPs were analyzed from all 3 brain regions to determine
which factors were highly expressed. We were able to determine that 5 out of these 15
were highly expressed in all 3 brain regions. These factors were hnRNPH1, Ddx17,
Rbfox1, Celf4, and Celf5. We hypothesized that aging and loss of E2 would alter
expression of these RBPs in a brain region specific manner. In chapter V, we
demonstrated that all 5 of these factors change in expression with age and increasingly
longer periods of E2 deprivation.
Changes in the expression of these RBPs can amount to varying effects within the
brain, mediated primarily by the alternative splicing patterns that they regulate.
HnRNPH1, Rbfox1, Celf4, and Celf5 are important RBPs that regulate alternative
splicing exon choices. The inclusion or exclusion of an exon can have immediate effects
upon the function of the protein, as evidenced by previous discussions on ERβ2. A
prominent feature of aging is the accumulation of proteins that may or may not be
functional [229]. Aberrant splicing of these transcripts might lead to accumulation of
mutant proteins [230]. Increased accumulation of alternatively spliced proteins that
undergo misfolding events, as evidenced by Tollervey and colleagues, include 11 disease
related proteins associated with neurodegeneration [149, 216].
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ERβ, it is possible that altered expression of these factors could directly or indirectly
affect this process. We know that hnRNPH1 is important for binding splicing site
silencers, and hnRNPs have been previously shown to have opposing effects on Nova1regulated alternative splicing events. Therefore it is possible that hnRNPH1 could
mediate inclusion of the ERβ2 insert in cooperation with the previously mentioned
SRSF2 (Fig. 34). Immediately downstream of the ERβ2 insert is a consensus sequence
that hnRNPH1 could theoretically bind, impairing assembly of the spliceosome to
assemble at this point to excise the insert-containing intron [62]. Rbfox1 can have similar
effects by blocking binding of splicing factor 1 (Sf1) to alternative exon branch points
[231]. This could result in alternative exon inclusion or exclusion events which may also
be possible due to several predicted Rbfox1 binding sites upstream and downstream of
the ERβ2 insert [62]. However, as displayed in Figure 35, an Rbfox1 site upstream of the
ERβ2 insert would result in its exclusion due to blockage of Sf1 binding (Figure 35B). If
Sf1 is able to bind to its consensus site, it mediates binding of the U2 snRNP to the
branch point, leading to RNA splicing of this intronic element, leaving the ERβ2 insert
intact (Figure 35C). Due to the importance of this factor in neuronal development, it is
most likely that maintenance of ERβ2 expression is important for mature neuron
differentiation and proper E2 signaling [212]. Lastly, Rbfox1 is an important regulator of
hnRNPH1 expression, making its opposing actions on ERβ2 alternative splicing more
succinct.
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Figure 34. hnRNPH1 and SRSF2 enhance ERβ2 expression. The consensus site for
hnRNPH1 is located downstream of the ERβ2 exon, whereas the SRSF2 site is upstream.
Binding of these RBPs to the pre-mRNA sequence of ERβ results in the alternative
splicing of ERβ to ERβ2 through enhanced spliceosomal assembly on the intronic
elements flanking the insert. SRSF2 mediates the removal of the upstream intron while
hnRNPH1 mediates the removal of the downstream intron, thus including the ERβ2
insert.
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Figure 35. The possible role of Rbfox1 on ERβ alternative splicing. (A) ERβ premRNA transcript contains Rbfox1 and Sf1 consensus sites upstream of the ERβ2 insert.
(B) If Rbfox1 binds to its site, it blocks the ability of Sf1 to bind to the alternative branch
point, therefore mediating exclusion of the alternative ERβ2 exon. (C) If Sf1 is able to
bind its site, it enhances U2 snRNPs recognition of this branch point through U2AF,
thereby including the ERβ2 exon within the mature transcript.
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Ddx17 is an important regulator of E2 signaling and gene regulation [207, 208, 232].
Like hnRNPH1, Ddx17 is also regulated by Rbfox1, and our data shows similar
expressional patterns for both RBPs within our E2 deprivation [212]. Increases in ERβ2
expression can impact E2 signaling, and changes in Ddx17 expression could compound
these effects. A subset of E2-regulated genes undergo RNA splicing under the control of
Ddx17 and knockdown studies of Ddx17 in MCF-7 cells resulted in decreased alternative
exon skipping events in GSK3β, an important kinase that phosphorylates and
stabilizes ERs [207]. The alternative exon in the GSK3β2 isoform encodes a 13 amino
acid sequence within the catalytic domain which reduces its kinase activity [233].
Interestingly, our findings observed only significant increases in Ddx17 expression,
which most likely would result in significant increases in expression of the more
catalytically active GSK3β1 isoform. GSK3β1 is important for maximizing sumoylation
of ERβ by small ubiqutin like modifier (SUMO)-1 to prevent protein degradation by
competing for ubiquitin acceptor sites [234]. Therefore, increased Ddx17 expression
through E2 treatment may be an attempt by the cell to protect the expression of ERβ
protein from ubiquitination via SUMO-1 in order to maintain ERβ expression similar to
the premenopausal state. SUMO-1 can also dictate ERβ transcriptional inhibition by
altering estrogen-responsive target promoter occupancy and gene expression, although
this has only been observed in breast cancer cells [234]. These findings did show that
ERβ protein can accumulate within the nucleus while not affecting ERβ-regulated gene
transcription, which could be a way the cell compensates for the loss in E2 is to sequester
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dependent transcription as soon as E2 is available.
Celf4 and Celf5 bind CUG repeat motifs within pre-mRNA transcripts, mediating
alternative splicing events [131, 235]. These RBPs are primarily expressed in the nervous
system and deficiency in Celf4 has been linked with aberrant excitatory
neurotransmission that can lead to seizures, a similar observation in Rbfox1-null mice
[129, 130]. CUG motifs are scattered throughout the ERβ pre-mRNA transcript, and
could be responsible for many RNA splicing events, including ERβ2. Interestingly, Celf4
sites have been shown to be enriched in Nova1-regulated exons [143]. Therefore, Celf4
and possibly Celf5 could be facilitating ERβ2 exclusion through coordination of Nova1,
as there is CUG motif within exon 5 (Figure 33).
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RNA-Binding protein

If RBP expression increases

Nova1

ERβ2 decreases

hnRNPH1

ERβ2 increases

Rbfox1

ERβ2 decreases

Celf4/5

ERβ2 decreases

Ddx17

Total ERβ decreases

Table 2. Summary of proposed actions of RNA-binding proteins on ERβ alternative
splicing.

	
  

Figure 36. Proposed model from results of aging, E2, ERβ, and Nova1 studies.
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There may be an answer to the potential issue arising from increased alternative
splicing of ERβ in the hippocampus with longer periods of ovarian hormone deprivation:
the trans-acting factors that act upon the pre-mRNA transcripts of ERβ. Splicing factors
like Nova1 are potential therapeutic targets. The findings from chapter IV demonstrate
the effects of aging and E2 deprivation on Nova1 expression, and as predicted these
changes occur in a region-specific manner. These studies support the hypothesis of my
dissertation, and these data provide novel findings that contribute to the field of
neuroendocrinology that could be applied to other important studies of aging in the
female brain.

	
  

CHAPTER VII
GENERAL METHODS

Ethics Statement
All animal protocols were approved by the Institutional Animal Care and Use
Committee (IACUC) at Loyola University Chicago, permit number 2009018.

Animals and deprivation paradigm
Female Fischer 344 rats (3 mo. and 18 mo. of age) were obtained from the NIH
aging colony (Taconic, Germantown, NY, USA). In this strain of rat, these ages equate to
young adult (3 months) and postmenopausal (18 months) ages as related to humans based
on calculations from rodent survival curves, reduced proestrous cycles and estradiol
concentrations, and increased cycle durations in 18+ month old Fischer 344 rats [180183]. Importantly, Fischer 344 female rats had an average lifespan of 26-29 months of
age, therefore an 18-month old rat would therefore have lived 62-69% of its life
expectancy. By contrast, women in the U.S. have an average life expectancy of 81.2
years (NCHS data brief, no 178, 2014). Therefore, a 55 year old woman is at 67% of her
total life expectancy, which is within the same range (62-69%) as an 18 month old Fisher
344 rat.
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Experiment #1: Comparison of ERβ2 and splicing factor expression in young (3
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mo.) and aged (18 mo.) female rats. Animals were bilaterally ovariectomized (OVX)
under vaporized isoflurane anesthesia, as previously described [210]. One week (7 d.)
following OVX, animals were administered a subcutaneous injection of vehicle
(safflower oil) or 2.5 µg/kg E2 (Sigma, Cat. No. E8875) (N=6-10/treatment group) based
on previous studies [210]. Treatments were administered once/day x 3 consecutive days.
Animals were humanely euthanized 24 hours after the last treatment, trunk blood was
collected, and brains were rapidly removed and flash frozen for tissue processing.

Experiment #2: Effects of varying lengths of E2 deprivation on ERβ2, splicing factors,
and RNAPII expression, and RNAPII activity in aged female rats. Aged (18 mo.) female
rats were OVX as described above and then separated into 4 groups that would undergo
increasingly longer periods of time without E2: 1, 4, 8, and 12 weeks (N = 1620/deprivation group; Figure. 2) [6, 7, 181]. After the assigned E2 deprivation period,
animals received a subcutaneous injection of either vehicle (safflower oil) or 2.5 µg/kg
E2 (Sigma, Cat. No. E8875) (N=6-10/treatment group). Treatments were administered
once/day x 3 consecutive days. Animals were humanely euthanized 24 hours after the last
treatment, trunk blood was collected, and brains were rapidly removed and flash frozen
for tissue processing. Net changes in animal weights are reported prior to OVX and 24
hours after final treatment in Table 3.
Groups of ovarian intact animals at all ages 3, 18, 19, 20, and 21 months of age
were used to compare to OVX animals (N = 6/age group).
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pre-op weight (g)
weight at sacrifice (g)
Treatment
vehicle
E2
vehicle
E2
1 week
285.4 ± 4.8
278.5 ± 6.8
280.8 ± 4.7
274.0 ± 6.8
4 weeks
268.5 ± 5.4
273.8 ± 9
277.8 ± 3.9
282.0 ± 8.9
8 weeks
272.0 ± 3.6
272.8 ± 5.8
298.2 ± 7.3
301.2 ± 4.8
12 weeks
280.5 ± 7.5
285.9 ± 6.7
312.7 ± 6.5
318.3 ± 4.2
Table 3. Body weights (g) of Fischer 344 rats before ovariectomy procedure and
after final treatment. There were no statistically significant differences in body weight
between treatment groups.

	
  

Experiment #3: Effects of ERβ and ERα selective agonists on ERβ2 and Nova1
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expression in aged (18 mo.) female rats. Aged (18 mo.) female rats were OVX as
described above. One week (7 d.) following OVX, animals were administered a
subcutaneous injection of vehicle (safflower oil), 2.5 µg/kg E2 (Sigma, Cat. No. E8875),
1 mg/kg diarylproprionitrile (DPN, Tocris, Cat. No. 1494), or 0.5 mg/kg propyl pyrazole
triol (PPT, Tocris, Cat. No. 1426) (N=6-10/treatment group) These doses were based on
previous studies demonstrative selective activation of their respective receptors [236,
237]. Treatments were administered once/day x 3 consecutive days. Animals were
humanely euthanized 24 hours after the last treatment, trunk blood was collected, and
brains were rapidly removed and flash frozen for tissue processing.

E2 concentration assay and vaginal cytology
Trunk blood was collected and centrifuged at 4500 RPM for 8 mins at 4°C. The
plasma samples first underwent a liquid-liquid extraction using diethyl ether to eliminate
interfering compounds in the plasma as previously described [238]. Following diethyl
ether extraction, samples were reconstituted using sample buffer contained in the 17βestradiol high sensitivity ELISA kit (Enzo Life Sciences, #AD 901 174), which was used
to determine concentration of circulating E2 within intact (N = 6/age), vehicle and E2treated (N = 6/age/treatment) animals per manufacturer's specifications. Absorbance was
measured on a BioTek Synergy HT plate reader. The sensitivity of the assay 14.0 pg/ml.
Interassay and intrassay coefficients of variance (CV) were 4.6% and 3.8%, respectively.
Cross reactivity with other endogenous estrogens were 17.8%, estrone and 0.9% estriol.

	
  

18-mo. animals prior to OVX had low circulating E2 levels (35.0 ± 7.1 pg/ml, N = 6).
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These low circulating E2 levels corresponded with consistent diestrous-like vaginal
cytology as assessed daily for 2 weeks prior to sacrifice (Figure 3A). Circulating E2
levels remained low in 18-mo. old animals treated with vehicle 1-week post-OVX (23.2 ±
2.7 pg/ml, N = 6). E2 treatment elevated levels in OVX animals (56.5 ± 6.3 pg/ml, N =
6), which is within physiological range of women who received hormone replacement
therapy during postmenopause (17-75 pg/ml) [34, 172]. Treatment with E2 increased
circulating levels consistently within this range throughout the deprivation paradigm (Fig.
3B). E2-treated 3-month old OVX animals (66.7 ± 8.2 pg/ml, N = 8) had levels similar to
diestrous intact animals at the same age (69.4 ± 15.2 pg/ml, N = 6).

Quantitative RT-PCR
Flash frozen brains were sectioned at 200 µm on a freezing microtome and
regions of interest were microdissected utilizing 0.75 mm Palkovit's brain punch tool
(Stoelting Co., Wood Dale, IL). The hypothalamus (-0.8 mm to -3.8 mm relative to
bregma), dorsal hippocampus (−2.30 to −4.16 mm relative to bregma), and ventral
hippocampus (4.30 to 6.04 mm relative to bregma) were all microdissected for RNA and
protein isolation. Brains were split sagittally for tissue collection where one hemisphere
was used for RNA isolation and the other for protein isolation in a non-biased manner.
RNA isolation was performed on sonicated tissue samples using Trizol reagent
(Invitrogen, #15596-026) according to the manufacturer’s specifications. All RNA
samples were quantified using Nanodrop spectrophotometry and analyzed for quality by

	
  

visualization of the RNA on 1.0% agarose gel. cDNA was reverse transcribed from
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1.0 µg RNA using High Capacity cDNA Reverse Transcription Kit (Applied Biosystems,
#4368814) according to manufacturer’s specifications. qRT-PCR for ERβ was performed
with TaqMan Gene Expression MasterMix (Applied Biosystems, #4369016) and TaqMan
custom FAM-probes that are specific for total ERβ and ERβ2 splice variants on an
Eppendorf Realplex4. HPRT was used as a reference gene to check loading and
normalize data, and was measured using TaqMan Gene Expression Assay
Rn01527840_m1. Total ERβ was measured by TaqMan Gene Expression Assay
Rn00562610_m1. The following custom probes sequences were designed and used to
detect rat ERβ splice variants: ERβ2 – TCCTCAGAAGACCCTCAC, ERβ1d3 & ERβ2d3 –
ATTCAAGGATCCAGGAGA, ERβ1d4 – GTCAAGTGTGGCTTTGTG. The following
primer sequences were used to detect the custom probes listed previously: ERβ2 forward
– AGCCTGTTGGACCAAGT, reverse – GCACTCTTCATCTGCGCAAC; ERβd3 &
ERβd4 forward – GAGAGACACTGAAGAGGAAGC, reverse –
TCACGGAACCTTGACGTCGTC.
qRT-PCR for RNAPII, Nova1, hnRNPH1, Rbfox1, Ddx17, Celf4, Celf5, and
HPRT were performed with Fast Start Universal SYBR Green Master Mix (Roche, Cat.
No. 04913914001) according to manufacturer’s specifications. Primer sequences were
designed and produced (Integrated DNA Technologies, Coralville, IA) in the sequences
outlined in Table 4. Data was analyzed by delta delta ct method as described previously
[239]. Briefly, the cycle detected for the gene of interest is subtracted from the cycle
detected for a housekeeping gene, which in this case is HPRT, resulting in the !Ct

	
  

value. The average !Ct of the reference group (such as our 3 month old vehicletreated animals) is subtracted from !Ct of the gene of interest at the data point in
question (ie. 18 month old E2-treated) which derives the !!Ct value. Fold change is
determined by taking 2-!!Ct. This Melting curves were performed after qRT-PCR to
ensure products of interest were correctly quantified.

134	
  

	
  

135	
  
Gene of interest
RNA
Polymerase II
Nova1
HPRT
hnRNPH1
Rbfox1
Ddx17
Celf4
Celf5

Direction of
sequence
Primer sequence (5' to 3')
Forward
GCTGGACCTACTGGCATGTT
Reverse
ACCATAGGCTGGAGTTGCAC
Forward
TTACCCAGGTACTACTGAGCG
Reverse
CCCATCAGGTTTCTGGGA
Forward
AGCAGTACAGCCCCAAAATGG
Reverse
TGCGCTCATCTTAGGCTTTGT
Forward
ACTTCCAGGGGAGGAGTACG
Reverse
GCCTCATCCTCTCAAAGCCA
Forward
TGCCCGTAAGATCGGTTGGA
Reverse
ATGTTGTCAACCTGTCCCCC
Forward
GCAACCTGAAGCAGGCTAGA
Reverse
GGTGCCTTGAGCATAGGTGT
Forward
CACCCTTACCCAGCACAGAG
Reverse
GGGGCAGATGGTAGATGAGC
Forward
CAGCGTGAAGGAGTTTGGAGA
Reverse
GGGAGGAGGGTTGAATGACG
Table 4. Primer sequences for genes of interest.

	
  

Cell culture experiments
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ERβ-positive hypothalamic-derived cells (GT1-7) were used for in vitro
experiments (generously provided by Dr. Pamela Mellon, University of San Diego, La
Jolla, CA) on ERβ2 expression in camptothecin treated studies [240]. Cells were
maintained in Dulbecco's Minimum Essential Medium (DMEM) 50:50 F12 media
containing glucose, L-glutamine, sodium pyruvate and 10% fetal bovine serum (FBS).
Cells were grown to confluency (70-80%) and media replaced with DMEM 50:50 F12
containing 10% dextran-charcoal stripped FBS for steroid free conditions 48 hours prior
to experiments. Cells were treated with either vehicle (DMSO, Fisher Scientific, #D128),
32 ng/µl camptothecin (Sigma, #C9911) alone, or camptothecin plus 100 nM E2 for 6
hours (N=3 plates/treatment group). All cell line experiments were done in triplicate to
ensure reproducibility. Cells were then collected for RNA isolation, cDNA synthesis, and
qRT-PCR as described above.
ERβ-positive hypothalamic-derived cells (IVB) and human embryonic kidney
cells (HEK) were used for all in vitro Nova1 overexpression and RNA
immunoprecipitation (RIP) experiments (generously provided by John Kaskow,
University of Cincinnati and Ed Campbell, Loyola University Chicago, respectively).
Cells were maintained in Dulbecco's Minimum Essential Medium (DMEM) media
containing glucose, L-glutamine, sodium pyruvate and 10% fetal bovine serum (FBS).
IVB cells were grown to confluency (70-80%) and were transfected with GFP-tagged
Nova1 in a dose-dependent manner (0.01 - 0.2ug DNA). pcDNA3Nova1 eGFP was a gift
from Nicolas Charlet-Berguerand (Addgene, Plasmid # 61275). PcDNA3 empty vector

	
  

was used as a negative control for the dose-dependent experiments. For RIP

137	
  

experiments, HEK cells were grown to confluency, then transfected with 3ug Nova1
eGFP and 3ug ERβ2 plasmid. PcDNA3 empty vector was used as a negative control. All
transfections utilized Continuum transfection reagent (Gemini Bio-Products, #400-700).
All cell line experiments were done in triplicate to ensure reproducibility. Cells were then
collected 24-48 hours later for RNA isolation, cDNA synthesis, and qRT-PCR as
described above.
RNA immunoprecipitation (RIP)
RIP experiments were performed using the Magna RIP RNA-Binding Protein
Immunoprecipitation Kit (EMD Millipore, #17-700) following manufacturer's
specifications. Briefly, HEK cells overexpressing Nova1 and ERβ2 were washed and
isolated with 10ml ice-cold PBS, then centrifuged at 1500RPM for 5 minutes. An equal
volume of RNA Lysis Buffer was used to resuspend pellet, then incubated on ice for 5
minutes in order to lyse the cells. Magnetic beads were pre-incubated with 2.5ug Nova1
antibody and 2.5ug rabbit IgG (EMD Millipore, Cat. No. PP64B) (negative control).
Antibody-coated beads were resuspended and then incubated with cell lysates rotating
overnight at 4°C. Supernatant was removed by centrifugation at 14K RPM for 30 min.
and beads were washed 6 times with RIP wash buffer. Following proteinase K treatment
at 55°C for 30 min., supernatant was removed from magnetic beads and placed in a new
tube for RNA isolation and cDNA synthesis. RIP analysis used the -2 delta delta CT
values for determining enrichment fold-change relative to IgG controls as previously
described [241].

	
  

Protein isolation and western blotting
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Hypothalamic, dorsal hippocampal, and ventral hippocampal tissue isolated from
aged female rat brains were placed in T-PER Tissue Protein Extraction Reagent (Thermo
Fisher Scientific, #78510) supplemented with 7x Protease and Phosphatase Inhibitor
cocktail (Thermo Fisher Scientific, #88668). Tissue was sonicated and insoluble material
including DNA was pelleted and excluded from the soluble portion of the extracts. 10 µg
protein was reduced in 4X laemmli buffer (Bio-Rad, #161-0747) at 95°C for 5 min. and
run on 10% SDS-PAGE gel. RNAPII expression and phosphorylation were blotted with
N-20 (sc-899, Santa Cruz Biotechnology) and 8A7 (sc-13583, Santa Cruz Biotechnology)
antibodies, respectively (Table 5). These antibodies detect the largest subunit of RNAPII
that binds DNA and conveys catalytic activity along with the second largest subunit that
forms the active center of the RNAPII enzyme [242, 243]. Nova1 protein expression was
detected with anti-Nova1 (Upstate/Millipore, Cat. No. #07-637) antibody that targets the
N-terminus and has been used previously [128]. Blots were imaged using a ChemiDoc
(Bio-Rad, Hercules, CA, USA) and quantified. Both RNAPII bands (2 largest subunits)
and Nova1 were quantified together using Image Lab 3.0 Software (Bio-Rad, Hercules,
CA, USA). Phosphorylated RNAPII (p-RNAPII), RNAPII, and Nova1 expression were
both normalized to β-actin expression with anti-β-actin (13E5) antibody (Cell Signaling,
Cat. No. #4970). A description of antibodies and amounts used can be found in Table 5.
The ratio p-RNAPII/RNAPII to determine activity of RNAPII relative to its expression
[244].

	
  

Peptide/protein Name of
target
Antibody
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Manufacturer, catalog #,
and/or name of
individual providing the
antibody
Santa Cruz Biotech (sc899)
Santa Cruz Biotech (sc13583)
Upstate/Millipore (07637)

Species raised
in; monoclonal
or polyclonal

Dilution
used

Pol II
Rabbit
1:1000
(N-20)
polyclonal
p-Pol II
Mouse
p-RNAPII
1:500
(8A7)
monoclonal
antiRabbit
Nova1
1:500
Nova1
polyclonal
β-Actin
Rabbit
β-Actin
Cell Signaling (4970)
1:1000
(13E5)
monoclonal
Table 5. Antibody table. RNAPII expression and phosphorylation were blotted with N20 (sc-899, Santa Cruz Biotechnology) and 8A7 (sc-13583, Santa Cruz Biotechnology)
antibodies, respectively. These antibodies detect the largest subunit of RNAPII that binds
DNA and conveys catalytic activity along with the second largest subunit that forms the
active center of the RNAPII enzyme. Nova1 expression was blotted with rabbit antiNova1 antibody (07-637, Upstate/Millipore). Blots were imaged using a ChemiDoc (BioRad, Hercules, CA, USA) and quantified. Both RNAPII bands (2 largest subunits)
Nova1, and β-actin were quantified together using Image Lab 3.0 Software (Bio-Rad,
Hercules, CA, USA). Phosphorylated RNAPII (p-RNAPII) and RNAPII expression were
both normalized to β-actin expression and then calculated as a ratio (p-RNAPII/RNAPII)
to determine activity of RNAPII relative to its expression. Nova1 expression was
normalized to β-actin expression.
RNAPII

	
  

Statistical Analysis
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Significant interactions were assessed by two-way ANOVA with age x treatment
as factors (Experiment 1: young vs. aged), or time x treatment (Experiment 2: E2
deprivation paradigm) using Systat 13 software (Systat Software Inc, San Jose, CA,
USA), followed by Tukey's Honestly-Significant-Difference post hoc analysis to
determine significant differences among groups where p<0.05. Different letters and/or
symbols denote statistically significant differences between groups. A separate Tukey's
Honestly-Significant-Difference post hoc test was utilized within groups that showed a
statistically significant main effect of age and/or treatment. A one-way ANOVA followed
by Tukey’s Honestly-Significant-Difference post hoc analysis was conducted to
determine significant difference (p<0.05) between selective ER agonists (DPN and PPT;
Exp. #3) where treatment was the main effect in the hypothalamus of 18-mo. animals and
in vitro studies. A paired t-test was used where noted if significant main effects or
interactions were not observed. All data are presented as mean +/- SEM.
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